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 Increases in the number of infectious disease outbreaks affecting humans have 
been reported nearly every decade since the 1940’s. Many of these outbreaks have been 
caused by emerging zoonotic viruses. It has recently been estimated that there are at least 
320,000 viruses in mammals that have yet to be discovered, some of which may affect 
humans. As humans continue to encroach upon previously isolated areas and have greater 
contact with wildlife, it is likely that zoonotic viruses will continue to emerge. Since 
many of these emerging viruses cause significant disease or death in humans it is vital 
that we study their pathology and pathogenesis in order to detect patterns in their 
mechanisms of disease, which could then be used to develop broad spectrum antivirals or 
vaccines. As such, we focused our studies on two recently emerged viruses, Nipah virus 
and the Middle East respiratory syndrome coronavirus (MERS-CoV), which have caused 
significant respiratory disease and death in humans. 
We used a Syrian hamster model to investigate whether differences in case 
fatality rates and prevalence of respiratory disease reported for Nipah virus outbreaks in 
Malaysia and Bangladesh were caused by intrinsic differences in the genomes of virus 
isolates from these outbreaks. We showed that hamsters developed similar end-stage 




differences reported between the outbreaks in Malaysia and Bangladesh were not due to 
viral genome heterogeneity. Rather, differences in transmission routes, viral dose, 
availability of healthcare facilities or willingness to seek medical care early in the 
infection may be responsible for the differences noted between these outbreaks. 
Additionally, we used Syrian hamsters to elucidate the early pathogenesis of Nipah virus. 
Nipah virus first targeted the lung and nasal cavity; virus replication was identified at 8 
hours post inoculation (hpi). Virus then spread to the larynx and trachea. Even at 48 hpi 
we did not detect infectious virus in the brain or infection of blood vessels in multiple 
organs. Results suggest that early administration of antivirals into the respiratory tract 
may prevent widespread infection of the vasculature and virus replication in the brain. 
 Since development of animal models is vital for studying novel viruses, we 
evaluated the available animal models of MERS-CoV infection. We found that transgenic 
mice expressing human dipeptidyl peptidase 4 were well-suited for screening antivirals 
and vaccines. Rhesus macaques and common marmosets were both suitable for 
transmission studies and confirming vaccine efficacy, while marmosets were ideal for 
confirming antiviral efficacy. Additionally, we compared the rhesus macaque and 
common marmoset models of MERS-CoV infection. We found that the increased clinical 
disease severity observed in marmosets, as compared to macaques, was most likely 
caused by increased pulmonary virus replication and development of more extensive 
acute bronchointerstitial pneumonia. These results suggest that treatments aimed at 
decreasing virus replication rates may dampen the acute pulmonary inflammatory 




CHAPTER 1. INTRODUCTION 
1.1 Emerging Infectious Diseases 
Increases in the number of infectious disease outbreaks affecting humans have been 
reported nearly every decade since the 1940’s.80,108 Many of these outbreaks have been 
caused by emerging infectious diseases, which include newly discovered diseases or 
known diseases whose incidence or geographic distribution has reportedly 
increased.14,37,102,147 The increase in the number of reported emerging infectious disease 
outbreaks has predominantly been attributed to changes in how humans interact with their 
environment. Increased international travel and trade have made it easier for infectious 
diseases to spread globally, while deforestation, agricultural expansion and urban spread 
have all allowed for increased contact between humans and wildlife.38,39 In fact, up to 
75% of reported emerging infectious diseases are zoonotic pathogens, which often 
originate in wildlife reservoirs, including bats.39,54,80,103,120,141,160 Emerging infectious 
diseases can be transmitted from an animal reservoir to humans by multiple means; some 
infectious diseases are thought to be transmitted directly to humans while others are 
indirectly transmitted to humans by way of an intermediate animal host.24,81 Detection of 
wildlife reservoirs is often complicated by the fact that these reservoirs are typically 




emerging infectious diseases to other species, including humans, can result in severe 
disease.21,92  
Although emerging infectious disease outbreaks can be caused by a wide array of 
infectious entities, a large percentage of these outbreaks have been caused by viruses, 
particularly RNA viruses.19,31,159,161 RNA viruses are more likely to cause emerging 
infectious disease outbreaks than DNA viruses because RNA viruses lack proofreading 
capabilities during genome replication, they have faster replication rates and a higher 
propensity for spontaneous genetic mutations.46,53,74,158 Emerging RNA viruses that 
specifically target the respiratory system can cause significant morbidity and 
mortality.55,59,69 Two recent examples of emerging RNA viruses that cause respiratory 
disease, and which will be reviewed further, are Nipah virus and the Middle East 
respiratory syndrome coronavirus.  
 
1.2 Nipah Virus 
 
1.2.1 The Initial Outbreak 
Nipah virus is a highly pathogenic biosafety level 4 (BSL-4) paramyxovirus in the 
genus Henipavirus. This virus was first isolated from the cerebrospinal fluid from a fatal 
human case during an outbreak that affected pigs and humans in 1998 to 1999; the initial 
outbreak originated in Malaysia and subsequently spread to Singapore.26,117 (Figure 1.1) 
During this outbreak, disease was first noted in pigs, followed by development of 
symptoms in humans. Younger pigs predominantly experienced respiratory disease with 




disease.101 Although, up to 100% of pigs on affected farms became infected, mortality 
rates were low.101 In cases where necropsies were performed on pigs, interstitial 
pneumonia, meningitis and widespread vascular damage were the main findings.101 Upon 
isolation and identification of Nipah virus in pigs, a mass culling of approximately one 
million pigs was performed by military personnel in Malaysia in order to end the 
outbreak.7 Unfortunately, shipment of Nipah virus infected pigs from Malaysia to 
Singapore, for slaughter, occurred prior to the culling of swine and resulted in the 
infection of 11 abattoir workers in Singapore.117 The Nipah virus outbreak in Singapore 
ended after importation of pigs from Malaysia was banned.24  
In Malaysia and Singapore, the vast majority of affected humans were Chinese 
men that worked on pig farms or had direct contact with pigs.8,22,60,135 Symptoms were 
typically reported within two weeks of exposure to pigs; in some cases individuals 
reported working with dying or sick pigs exhibiting respiratory disease, prior to onset of 
their symptoms.60,116 Affected humans often developed a fever, encephalitis accompanied 
by neurologic signs, headache or reduced levels of consciousness, and respiratory disease 
that presented as a nonproductive cough and sore throat, which in some cases was 
accompanied by abnormal chest radiographs and atypical pneumonia.22,26,49,60,117,144 
Additional symptoms in some patients included myalgia, vomiting, hypertension, profuse 
sweating and tachycardia.22,60 Lymphopenia, thrombocytopenia and hyperglycemia were 
reported in some individuals.22,135 Nipah virus was isolated from tracheal secretions and 
throat swabs, nasal secretions, cerebrospinal fluid and urine.28,29,60 During this outbreak, 
265 human cases of Nipah virus infection were reported in Malaysia; the case fatality rate 




predominantly within the brain and lung; vascular lesions were often associated with 
infarcts and/or parenchymal inflammation.26,87 Affected blood vessels were characterized 
by vasculitis, fibrin thrombi, fibrinoid change and/or formation of endothelial 
syncytia.26,157 Occasionally, splenic lymphoid depletion, necrotizing splenitis and/or 
lymphoid necrosis were observed.157 
 
1.2.2 The Emergence of Nipah Virus in Bangladesh and India 
Cases of Nipah virus infection in humans in Malaysia or Singapore have not been 
identified since the initial outbreak ended in 1999; however, Nipah virus has emerged in 
Bangladesh and India. The first outbreak in Bangladesh occurred in 2001 and almost 
yearly outbreaks have been reported since.77,89,123 In India, Nipah virus outbreaks in 
humans were detected in 2001 and 2007 in regions that bordered areas of Bangladesh 
where outbreaks had previously been detected.10,18 In Bangladesh and India, there was no 
evidence of illness in pigs prior to the detection of human cases of Nipah virus infection 
and contact with pigs was not found to be a risk factor for Nipah virus infections in these 
regions.77 Unlike the initial Nipah virus outbreak which mainly affected adult males, the 
outbreaks in Bangladesh spanned a wide age range, from children to the elderly, and 
typically involved both males and females.90,133 Similar to the outbreak in Malaysia and 
Singapore, fever, encephalitis and respiratory disease were reported and occasional 
development of gastrointestinal distress, including vomiting and diarrhea, was noted.76,123 
Although a case fatality rate of up to 100% has been reported in individual outbreaks, no 
autopsies have been performed on fatal human cases and descriptions of the histologic 




1.2.3 A Comparison of Nipah Virus Outbreaks 
Although the outbreak in Malaysia and Singapore and the ongoing outbreaks in 
Bangladesh and India were all caused by Nipah virus, key differences occurred in these 
distinct geographic regions. Differences in the prevalence of respiratory disease, case 
fatality rates, degree of genetic similarity among Nipah virus isolates, proposed routes of 
transmission to humans and presence or absence of an intermediate host have been noted. 
In the initial Nipah virus outbreak, respiratory disease was observed in close to 30% of 
infected humans and the case fatality rate was approximately 40%.22,116,117 However, in 
the outbreaks in Bangladesh and India both the prevalence of respiratory symptoms and 
the case fatality rates were higher. In individual outbreaks, up to 75% of affected humans 
developed respiratory disease and a case fatality rate of up to 100% was reported.10,132,155 
There was minimal genetic heterogeneity among virus isolates from the Malaysia 
outbreak; in fact, Nipah virus isolates from the lungs of infected pigs had genetic 
sequences identical to those from humans.1,124 These results suggest that Nipah virus was 
directly transmitted from pigs to humans and that perhaps there was only a single 
introduction of Nipah virus into the pig population. Nipah virus isolates from the 
Bangladesh outbreaks exhibited substantial genetic heterogeneity, suggesting that the 
virus was spread to humans on several occasions and multiple isolates were circulating in 
affected humans.86 Nipah virus isolates from Malaysia and Bangladesh were distantly 
related. Although these virus isolates are considered to be one species, it has been 
proposed that they represent two different genotypes since they share only 91.8% 




and Bangladesh, two countries that border each other, were genetically similar enough to 
suggest that they were derived from a common (bat) source.10,18 
Differences have been noted in the proposed transmission cycles of Nipah virus in 
Malaysia and Singapore as compared to Bangladesh and India. (Figure 1.2) In Malaysia, 
flying foxes were thought to transmit the virus to pigs which acted as an intermediate, 
amplifying host that transmitted Nipah virus to humans. Flying foxes, a type of bat, are 
an asymptomatic reservoir host and excrete Nipah virus in their saliva and 
urine.27,50,67,99,124,129,162,164 Pigsties in Malaysia are typically outdoors and some have been 
located adjacent to fruit orchards, including those that grew mangos.122 It is suspected 
that pigs became infected with Nipah virus after ingesting partially eaten mangos that 
were contaminated by flying fox saliva laden with Nipah virus, after the fruit dropped 
into an open air pigsty.25,144 Nipah virus then rapidly spread among pigs, likely through 
contact with oral or respiratory secretions or urine.100 Humans were most likely infected 
by direct contact with Nipah virus infected pigs and their secretions.8,20,116,144 In 
Singapore, abattoir workers became infected when they contacted pigs imported from a 
Nipah virus infected farm in Malaysia.117 Conversely, in the outbreaks in Bangladesh and 
India, Nipah virus was thought to be transferred from fruit bats to humans with no 
intermediate host.77 Flying foxes have been observed feeding from pots collecting date 
palm sap in Bangladesh, potentially contaminating the sap with saliva or urine that 
contained Nipah virus.90,123 Furthermore, human collection and ingestion of date palm 
sap is seasonal, occurring from December to March, and coincides with the ongoing 
outbreaks of Nipah virus.88 Humans likely became infected after they ingested raw date 




nosocomial and human-to-human transmission of Nipah virus have been reported, 
usually after close contact with a human that was exhibiting respiratory 
symptoms.18,64,75,132 Person to person transmission was not documented in the outbreak in 
Malaysia and Singapore.104 
 
1.2.4 Nipah Virus Tissue Tropism and Host Range 
Although differences between Nipah virus outbreaks in various geographic 
regions have been identified, the respiratory system, central nervous system, vasculature 
and lymphoid system appeared to be consistently targeted. The tissue predilection 
coincides with the locations of the receptors for Nipah virus, ephrin B2 and ephrin 
B3.15,109,110 Receptors for Nipah virus have been detected on epithelial cells, arterial 
endothelial cells, arterial smooth muscle cells, neurons and T lymphocytes.51,56,83,115,136,165 
Ephrin B2 and ephrin B3 are highly conserved proteins, which may explain the broad 
host range reported for Nipah virus.16,93 In addition to humans, pigs and flying foxes, 
natural infections have also occasionally been detected in goats, horses, dogs and 
cats.82,139,144 Additionally, several animal species are permissive to experimental Nipah 
virus infections, including laboratory rodents, chicken embryos, cats, ferrets and 
nonhuman primates; however, some of these models only recapitulate certain aspects of 







1.2.5 Animal Models of Nipah Virus Infection 
 
1.2.5.1 Mouse Models of Nipah Virus Infection 
Depending on the model, mice are either asymptomatic, exhibit respiratory and 
vascular lesions or develop neurologic, respiratory and vascular disease. Intranasal 
inoculation of wildtype C57BL/6 and BALB/c adult and young adult mice with either the 
Nipah virus isolate from Bangladesh or Malaysia resulted in asymptomatic, transient 
infection of the lungs.48 Although viral RNA was detected in the lungs at 21 days 
postinoculation, pulmonary lesions did not develop. Additionally, neither lesions nor 
viral RNA were present in the brain and viremia was not detected. A second mouse 
model that mimicked some aspects of respiratory damage reported in humans has been 
developed. In this model, human lung xenografts were subcutaneously transplanted into 
NSG mice, then the Malaysia Nipah virus isolate was directly injected into the 
xenografts.145 The human lung xenografts developed endothelial and bronchial and 
alveolar epithelial syncytia, vascular fibrinoid change and pulmonary necrosis 
accompanied by hemorrhage; pulmonary inflammation was minimal. High viral titers 
were present in the human lung and viremia was noted in the mice. Despite the viremia, 
lesions were not detected outside the human lung xenografts and mice did not exhibit any 
clinical signs. While the human lung xenograft model in NSG mice only demonstrates 
some features of human Nipah virus infection, an IFNAR knockout mouse model 
develops vascular, nervous system and respiratory system lesions. Inoculation of IFNAR 




route caused weight loss and neurologic disease.45 The intraperitoneal and intracerebral 
inoculation routes were uniformly lethal, while intranasal inoculation with the same dose 
was fatal in 60% of animals. Histologically, all inoculation routes were able to cause 
meningoencephalitis, widespread vasculitis and necrotizing alveolitis. Unfortunately, this 
animal model did not exhibit lymphoid organ lesions, which have been reported in some 
fatal human Nipah virus infections. 
 
1.2.5.2 A Domestic Cat Model of Nipah Virus Infection 
Experimental oral and intranasal inoculation of domestic cats with the Nipah virus 
Malaysia isolate resulted in fever, tachypnea, open-mouth breathing and dyspnea.100 
Histologically, there was pulmonary hemorrhage and edema, pulmonary infarcts, 
tracheobronchitis and syncytia in the endothelial, alveolar epithelial and bronchiolar 
epithelial cells. Vasculitis or fibrinoid change were prominent in the lungs, spleen, lymph 
nodes and meninges. Necrosis was detected in lymphoid organs. Mild nonsuppurative 
meningitis was observed adjacent to meningeal arteritis in one cat. Nipah virus antigen 
was identified, by immunohistochemistry, in the lung, trachea, meningeal endothelium 
and spleen. Although the cat model replicates the severe respiratory clinical disease and 
pulmonary, vascular and lymphoid lesions seen in some Nipah virus infected humans, 
encephalitis and neurological clinical signs, which are common in humans infected with 





1.2.5.3 A Chicken Embryo Model of Nipah Virus Infection 
Injection of the Nipah virus Malaysia isolate into the allantoic cavity or yolk sac 
of chicken embryos resulted in severe, often lethal, central nervous system lesions and 
multisystemic vascular disease.140 Histologically, Nipah virus antigen colocalized with 
lesions. Unfortunately, clinical disease cannot be evaluated in chicken embryos and 
pulmonary disease was absent in this model. 
 
1.2.5.4 A Guinea Pig Model of Nipah Virus Infection 
Intraperitoneal inoculation of guinea pigs with the Nipah virus Malaysia isolate 
has caused varying degrees of disease. In one experiment, inoculated guinea pigs 
developed severe vascular and nervous system disease that was fatal in approximately 
93% (26 out of 28) of the animals, while a much smaller pilot study reported transient 
fever and weight loss in two inoculated guinea pigs.142,156 In the study by Torres-Velez et 
al, the most prominent lesions were vasculitis and fibrinoid change in all affected 
tissues.142 Similar to humans, guinea pigs also developed meningitis or 
meningoencephalitis and lymphoid depletion and necrosis in the spleen.142 However, only 
50% of guinea pigs displayed brain lesions. In addition, only 1 of 22 guinea pigs 
developed pulmonary lesions, indicating that guinea pigs are not a reliable model of 
Nipah virus respiratory disease.142 Moreover, there was a unique predilection for vascular 
damage in the urinary bladder and reproductive organs of guinea pigs, which has not 




Individually, the mouse, cat, chicken embryo and guinea pig models of Nipah 
virus infection only exhibit some facets of human Nipah virus disease. In contrast, the 
Syrian hamster, ferret and African green monkey models of Nipah virus infection 
recapitulate the respiratory and neurologic disease, vasculotropism and lymphoid organ 
damage described in infected humans. 
 
1.2.5.5 A Ferret Model of Nipah Virus Infection 
Ferrets oronasally inoculated with either the Bangladesh or Malaysia isolates of 
Nipah virus developed severe neurologic and/or respiratory disease.30 Clinical signs 
included fever, dyspnea, ataxia, limb paralysis and facial or limb tremors. Histologically, 
there was necrotizing bronchoalveolitis, lymphadenitis and rhinitis, widespread vasculitis 
and meningitis. Despite the prominent neurological clinical signs, encephalitis was not 
detected in any of the ferrets. Immunohistochemistry identified viral antigen in the 
respiratory system, vasculature, including vessels in the brain, and lymphoid organs. 
Blood and essentially all tissues examined contained viral RNA, indicating systemic 
distribution of the virus. Although, the respiratory, lymphoid and nervous systems were 
affected in ferrets, a major limitation of this model was the absence of encephalitis in all 
animals. 
 
1.2.5.6 An African Green Monkey Model of Nipah Virus Infection 
Intratracheal inoculation of African green monkeys with the Malaysian isolate of 




nervous systems and vasculature.58,79 Clinical signs included tachypnea, dyspnea, open-
mouth breathing, fever, tachycardia, weight loss, hypotension and tremors.58,79 
Radiographs showed evidence of pleural effusion in most of the primates that exhibited 
open-mouth breathing, and pneumonia or pulmonary congestion.58 Severe respiratory 
distress was observed in most fatal cases.79  Similar to some Nipah virus infected 
humans, thrombocytopenia and hyperglycemia were observed in a few monkeys.58,79 At 
necropsy, varying numbers of animals exhibited frothy fluid exuding from their nose and 
mouth, pulmonary edema and congestion, urinary bladder mucosal hemorrhages and 
meningeal congestion.58 Histologically, there was multiorgan vasculitis with endothelial 
syncytia or fibrin thrombi.79 Infarcts were detected adjacent to fibrin thrombi.79 
Interstitial pneumonia, meningoencephalitis and necrohemorrhagic splenitis and 
lymphadenitis coincided with the presence of viral antigen, as detected by 
immunohistochemistry.79 Viremia was detected in multiple monkeys and viral RNA was 
found in essentially every organ system.58 Although the African green monkey model 
recapitulated the disease observed in human cases of Nipah virus infection, African green 
monkeys can be difficult to handle in BSL-4 laboratories, which are required for working 
with Nipah virus, and there are ethical issues that arise when primates are used for 
research.  
 
1.2.5.7 A Syrian Hamster Model of Nipah Virus Infection 
Similar to African green monkeys, Syrian hamsters emulated human Nipah virus 




hamsters with either the Bangladesh or the Malaysia isolate of Nipah virus.40,42,44,107,130,156 
Similar clinical signs and lesions have been reported for either intraperitoneal or 
intranasal inoculation.156 Hamsters exhibited respiratory clinical signs such as labored 
abdominal breathing and neurologic disease, including seizures, limb paralysis, muscle 
twitching and ataxia.44,156 Inoculation with a high viral dose may result in both respiratory 
and neurologic clinical signs, or solely respiratory disease, while lower viral doses 
typically only cause neurologic disease.44,130 Infected hamsters developed 
bronchointerstitial pneumonia, multiorgan vasculitis with endothelial syncytia and 
fibrinoid change, rhinitis, meningitis or meningoencephalitis with infarcts and rare foci of 
splenic necrosis.40,42,107,156 Immunohistochemistry and in situ hybridization have been 
used to detect viral antigen and RNA, respectively, in the lung, brain and spleen.156 
Syrian hamsters have been used to model the pathogenesis of Nipah virus infection, they 
have also been integral in showing that Nipah virus can be shed in nasal and 
oropharyngeal secretions and could be transmitted by direct contact, ingestion of Nipah 
virus in artificial date palm sap, or potentially be transmitted by fomites.40,42 Although 
both the Syrian hamster and African green monkey models of Nipah virus recapitulate 
the clinical presentation and histologic lesions documented in humans, the Syrian hamster 
has the added benefits of being easy to obtain, being easy to handle in BSL4 laboratories 
and there are fewer ethical objections to its use in research, as compared to primates. 
Thus, the Syrian hamster model was chosen to study the respiratory tract pathology and 
early pathogenesis of the Malaysia and Bangladesh isolates of Nipah virus, which are 





1.2.6 A Second RNA Virus Emerges in Humans 
Less than 15 years after the emergence of Nipah virus in Malaysia, a case of 
pneumonia caused by a novel RNA virus was diagnosed in a man in Saudi Arabia. That 
emergent respiratory virus was isolated, classified as a lineage C betacoronavirus and 
eventually called the Middle East respiratory syndrome coronavirus. Details of the rise of 
this novel respiratory disease will be discussed forthwith. 
 
1.3 Middle East Respiratory Syndrome Coronavirus (MERS-CoV) 
 
1.3.1 The Emergence of MERS-CoV 
Middle East respiratory syndrome coronavirus (MERS-CoV) was first isolated 
from a man with fatal pneumonia in 2012; since then the virus has infected individuals in 
25 countries, including the United States.154,167 (Figure 1.3) In some countries, only 
individual cases have been reported, while in other locations cluster outbreaks have 
developed. The majority of affected individuals have resided in, or recently traveled to, 
the Middle East. Most recently, a Korean national traveled to the Middle East and upon 
return to Korea developed clinical disease and was diagnosed with MERS.153 
Subsequently, there have been almost daily increases in the number of human MERS-
CoV infections in the Republic of Korea; more than 180 laboratory confirmed human 
MERS-CoV cases have been detected and linked to healthcare settings.152 Worldwide, 
more than 1300 cases of human MERS-CoV infection have been identified and more 





1.3.2 Human MERS-CoV Infections 
Although the first identified case of MERS-CoV infection in a human resulted in 
fatal pneumonia, subsequent cases have shown that MERS-CoV can cause a wide 
spectrum of disease severity, ranging from asymptomatic to fatal, fulminant respiratory 
disease.95,113,114 The incubation period has been estimated to range from approximately 2 
to 15 days, with a median incubation period of 5 days.11 Fever and respiratory symptoms, 
such as coughing, dyspnea, rhinorrhea and sore throat are often the presenting 
complaints.113,114 Respiratory disease has typically been accompanied by pulmonary 
infiltrates, as observed by computed tomography (CT) or radiographs.11,63 Neutrophils 
and increased numbers of macrophages have been detected by cytology on 
bronchoalveolar lavage samples.63 Some patients also exhibited myalgia, fatigue, 
hemoptysis, diarrhea or abdominal pain.94,113 Lymphopenia, neutrophilia and/or 
thrombocytopenia are often detected on complete blood counts.63,114,167 Serum 
biochemistry panels from some patients have displayed increased alanine transaminase, 
lactate dehydrogenase and creatinine, suggesting liver and renal damage have 
developed.11,114 Acute respiratory distress syndrome, acute renal failure, multiorgan 
failure or shock have occurred late in the disease course in some patients.63,114 Median 
time from symptom onset to development of severe disease has been reported to be 5 
days, while progression from symptom onset to death took on average 11 days.11 
Currently, the overall case fatality rate is approximately 36%.152 Comorbidities, including 
cardiac or renal dysfunction, hypertension, obesity, smoking, diabetes mellitus, 
immunosuppressive diseases or cancer have been detected in many of the individuals that 




typically been reported in immunocompetent, previously healthy individuals.138 
Originally, the vast majority of MERS-CoV cases were diagnosed in middle-aged 
males.11,113 However, overall, males now make up only about 66% of reported cases and 
MERS-CoV infections have been identified in all age groups, ranging from infants to the 
elderly.154  
 
1.3.3 MERS-CoV Transmission 
Although the exact route of MERS-CoV transmission to humans has not been 
determined, it is suspected that the virus has been zoonotically transmitted from bats to 
humans, or from bats to camels to humans. (Figure 1.4) Evidence suggests that bats may 
serve as a reservoir for MERS-CoV and/or its viral ancestor. Lineage C 
betacoronaviruses that are phylogenetically similar to MERS-CoV in humans and camels 
have been detected in multiple bat species.9,78,84,146,163 Additionally, 100% sequence 
homology was detected for a 200 nucleotide fragment of the RNA-dependent RNA 
polymerase of the original human MERS-CoV isolate and a virus isolate collected from a 
bat in Bisha, Saudi Arabia near the home of the man from which the first isolate of 
MERS-CoV was detected.96 Although PCR results from bats indicate that bats could 
serve as a source of MERS-CoV infection for humans, contact between bats and humans 
is limited. Additionally, the development of several, geographically separated cluster 
outbreaks of MERS-CoV infections in humans indicates that zoonotic transmission to 
humans has likely occurred on multiple occasions, suggesting that another animal species 
in more frequent contact with humans may act as an intermediate host.35,36 Dromedary 




CoV and are common in Middle Eastern countries that have reported high numbers of 
human MERS-CoV infections.61 
Dromedary camels are thought to harbor MERS-CoV. MERS-CoV specific 
neutralizing antibodies have been detected in the serum of a high percentage of 
dromedary camels in several countries, including the United Arab Emirates and Saudi 
Arabia which are countries that have also reported high numbers of human MERS-CoV 
infections.6,71,72,98,112,119,128 Serological evidence indicates that MERS-CoV or a MERS-
CoV-like virus has been infecting camels for approximately the last 30 years.105 In 
addition, MERS-CoV RNA and infectious virus have been isolated from dromedary 
camels.5,12,23,65,166 Camels appear to be infected with MERS-CoV early in life.5,6 Camels 
are permissive to experimental MERS-CoV infection; MERS-CoV inoculated camels 
exhibit mild upper respiratory tract disease with mild to moderate inflammatory lesions in 
the nasal cavity, trachea, bronchi and bronchioles.2 MERS-CoV infections in camels 
appear to be transient and either asymptomatic or result in mild respiratory disease, such 
as rhinorrhea.2,12 It is suspected that virus transmission between camels and humans may 
occur through close contact with camel respiratory secretions; high viral loads have been 
detected in nasal discharge and conjunctival and nasal swabs from camels.2,112 Multiple 
individuals diagnosed with MERS-CoV have reported contact with camels prior to onset 
of their symptoms.95,121 In fact, on multiple camel farms MERS-CoV RNA has been 
detected in nasal swabs collected from camels exhibiting respiratory disease and from 
humans caring for the ill camels.12,94 Phylogenetic analysis of viral genomes from 
affected humans and their camels showed the virus isolates were either identical or 




between these two species.12,65,94 In these cases, zoonotic transmission was thought to 
have occurred through close contact with infected camels and their respiratory 
secretions.12,94 Although respiratory transmission may play a major role in zoonotic 
transmission of this virus, foodborne transmission through ingestion of raw camel milk 
containing MERS-CoV has not been ruled out. MERS-CoV RNA has been detected in 
milk from camels.127 Additionally, infectious MERS-CoV has been shown to be stable 
for a prolonged time period in refrigerated unpasteurized camel milk.148 In the Middle 
East, consumption of raw camel milk is not uncommon and some individuals have 
reported ingesting unpasteurized camel milk prior to contracting MERS-CoV.121 
Interestingly, although seroprevalence studies have suggested that MERS-CoV infections 
are a common, widespread problem in populations of dromedary camels in Africa and the 
Middle East, some countries with MERS-CoV infected dromedary camels have yet to 
report human MERS-CoV infections, suggesting that camel to human transmission is 
limited.34,70,105,128 
  In addition to the proposed zoonotic transmission of MERS-CoV, human-to-
human transmission has been documented, although tends to be infrequent, with the 
exception of the recently described outbreak in the Republic of Korea where human-to-
human transmission has resulted in numerous cases. Incidences of MERS-CoV 
transmission among family members have been reported.47,97,114,138 Additionally, 
nosocomial transmission between patients and from patients to visitors or health care 
personnel has been documented frequently.4,11,63,73,91,113 In fact, in some outbreak clusters 





1.3.4 The Pathology of MERS-CoV (and SARS-CoV) in Humans 
Although over 400 human MERS-CoV infections have been fatal to date, published 
autopsy results are not yet available.152 This is in part due to cultural and religious 
practices in the geographic regions where most MERS-CoV infections have occurred. 
Therefore, the histologic lesions caused by MERS-CoV infections in humans have yet to 
be characterized. However, MERS-CoV cases have many clinical features in common 
with infections caused by severe acute respiratory syndrome coronavirus (SARS-CoV). 
SARS-CoV, which emerged in 2002 in China and caused outbreaks in several countries 
in 2003, is a betacoronavirus related to MERS-CoV.131,151 Similar to MERS-CoV, SARS-
CoV caused fever and respiratory disease, often resulting in acute respiratory distress 
syndrome, with some individuals also exhibiting gastrointestinal distress and 
myalgia.85,118 Thoracic imaging (radiographs or CT), hematology, and serum 
biochemistry results of MERS-CoV can be indistinguishable from those of SARS-CoV.85 
As for MERS-CoV, SARS-CoV was thought to be transmitted from a primary animal 
reservoir, likely horseshoe bats, to an intermediate animal host, civet cats, and then 
transmitted to humans.57,62,143 Subsequent human-to-human and nosocomial transmission 
was documented for SARS-CoV, with many cases involving healthcare workers.85 
Although the overall case fatality rate for SARS-CoV was only around 10%, gross and 
histologic lesions were characterized for this disease using autopsy and pulmonary biopsy 
specimens.111,151 Because of the similarities, it is suspected that fatal human MERS-CoV 
cases will have lesions comparable to those described for SARS-CoV. In humans 
infected with SARS-CoV, pulmonary consolidation was noted at autopsy.85 




desquamation of pneumocytes and alveolar and interstitial inflammation.85,111 
Multifocally, pneumocytes were multinucleated and vacuolated or exhibited cytomegaly 
and had abundant amphophilic, granular cytoplasm.85,111 Fibrin thrombi, bronchial 
epithelial erosions and bronchiolitis obliterans were also observed.111 Histologic features 
similar to those described for SARS-CoV infections develop in animal models of MERS-
CoV. Even though MERS-CoV and SARS-CoV bind different receptors, the expression 
pattern for the MERS-CoV receptor coincides with the distribution of lesions in human 
SARS-CoV infections. 
 
1.3.5 Tissue Tropism and Host Range of MERS-CoV 
The receptor for MERS-CoV is dipeptidyl peptidase 4 (DPP4), also known as 
CD26.125 DPP4 is a conserved type II transmembrane glycoprotein expressed by 
bronchial and bronchiolar respiratory epithelium, pulmonary endothelium and vascular 
smooth muscle, alveolar macrophages and type I and type II pneumocytes in multiple 
species.43,52,125,149 The receptor-binding domain of the MERS-CoV spike protein (S) is 
responsible for binding of the virus to DPP4 on the host cell membrane.150 The amino 
acid sequence of DPP4 restricts the host range of MERS-CoV; 14 amino acids in DPP4 
appear to be critical in determining whether MERS-CoV S can bind to DPP4.137,150 
Human, camel, and bat DPP4 can bind MERS-CoV S, whereas multiple laboratory 
animal species often used to model viral infections have significant differences in the 
amino acid structure of their DPP4 binding region, which prevents MERS-CoV from 
binding and entering host cells.13,149 Wildtype mice, ferrets and Syrian hamsters are 




and common marmosets are permissive to MERS-CoV infections and the region of DPP4 
that binds MERS-CoV in these nonhuman primate species is identical to that in 
humans.43,52,149 As there are still many gaps in our knowledge of human MERS-CoV 
infections, the development of animal models for this recently emerged respiratory 
disease is of utmost importance. 
 
1.3.6 Animal Models of MERS-CoV Infection 
Although most laboratory rodents were resistant to MERS-CoV infection, several 
animal species were permissive, including New Zealand white rabbits, rhesus macaques 
and common marmosets.43,52,66,106 In addition, human DPP4 expressing transduced and  
transgenic mice permissive to MERS-CoV infection have been developed.3,168 The extent 
to which each of these species developed clinical disease and lesions varied. New 
Zealand white rabbits inoculated with MERS-CoV were asymptomatic, yet developed 
mild upper and lower respiratory tract lesions and infectious virus could be isolated from 
their lungs.66 Human DPP4 transduced mice exhibited minor weight loss or lack of 
weight gain, mild pulmonary congestion and interstitial pneumonia; however, disease and 
human DPP4 expression were both transient.168 In human DPP4 transgenic mice, severe 
respiratory disease developed, which was 100% fatal; pulmonary consolidation was seen 
grossly and bronchointerstitial pneumonia was observed microscopically.3 Fever and 
mild to moderate respiratory disease accompanied by bronchointerstitial pneumonia with 
hyaline membranes were observed in rhesus macaques.43,106 Common marmosets 
exhibited severe respiratory disease and widespread bronchointerstitial pneumonia with 




of MERS-CoV infection is available in Chapter 4 and an in depth comparison of the 
respiratory tract pathology and pathogenesis of MERS-CoV in the rhesus macaque and 
common marmoset models can be found in Chapter 5. 
 
1.4 Conclusion and Hypotheses 
Multiple emerging viral infections that cause human respiratory disease have been 
discovered within the last 15 years. Many of these emerging infectious diseases have 
been transmitted from a wildlife reservoir to humans, making it difficult to control or 
prevent human disease. As the number of reported emerging infectious disease outbreaks 
has steadily increased since the 1940’s, development of animal models is vital for 
determining the pathogenesis of these emerging pathogens. A better understanding of the 
pathogenesis combined with the availability of robust animal models enables 
development and efficacy testing of antivirals and vaccines. The research presented here 
was undertaken to improve our understanding of the respiratory tract pathology and 
pathogenesis of two emergent viral infections.  
We first set out to elucidate whether a Nipah virus isolate from Bangladesh (NiV-
B) and a Nipah virus isolate from Malaysia (NiV-M) caused comparable late stage 
respiratory tract lesions in a Syrian hamster model. We hypothesized that “NiV-B would 
cause more severe late stage respiratory pathology than NiV-M, due to the higher case 
fatality rate and prevalence of respiratory disease reported in humans in the Bangladesh 
outbreaks, as compared to the Malaysia outbreak.” In addition to understanding the late 
stages of Nipah virus disease, we also wanted to identify the target organ systems and cell 




its initial target cells to end-stage disease could be mapped. Based on epidemiologic data 
from human outbreaks and information on the late stages of disease in animal models of 
Nipah virus, we hypothesized that “Nipah virus binding and replication for both NiV-B 
and NiV-M would first occur in the respiratory and olfactory epithelium in the nasal 
cavity and in the pulmonary pneumocytes.” 
For MERS-CoV, we evaluated available animal models of MERS-CoV infection 
in regard to their ability to recapitulate the clinical presentations observed in human 
MERS-CoV cases and their development of respiratory tract pathology. Then we 
compared the respiratory tract pathology and pathogenesis of MERS-CoV in two recently 
developed nonhuman primate models. We hypothesized that “the increased clinical 
disease severity reported in the common marmoset model of MERS-CoV, as compared to 
the rhesus macaque model, was caused by increased virus replication in the lungs and 
development of more extensive pulmonary lesions.”  
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Figure 1.1 Geographic distribution of human Nipah virus outbreaks. Countries where 
outbreaks have occurred are shown in tan. Numbers indicate the cumulative number of 






Figure 1.2 Proposed transmission cycles for Nipah virus in the outbreaks in Malaysia (A) 
and Bangladesh (B). A. In Malaysia, Nipah virus was likely transmitted from flying 
foxes, which serve as a reservoir for Nipah virus, to pigs, through ingestion of partially 
eaten mangos that were contaminated with flying fox saliva or urine that contained Nipah 
virus. Nipah virus then rapidly spread among pigs, likely through contact with Nipah 
virus infected pig oral or respiratory secretions or urine. Transmission of Nipah virus 
from pigs to humans was most likely caused by humans coming into direct contact with 
Nipah virus infected pigs and their secretions. Human-to-human transmission was not 
detected in the Nipah virus outbreak in Malaysia. B. In Bangladesh, Nipah virus was 
thought to have been transmitted from flying foxes to humans, by humans ingesting date 
palm sap contaminated with flying fox urine or saliva that contained Nipah virus. The 
contamination of date palm sap likely occurred when flying foxes were feeding from the 
pots that were collecting date palm sap. Subsequently, human-to-human transmission of 
Nipah virus was reported, this was thought to occur through close contact with 






Figure 1.3 Geographic distribution of Middle East respiratory syndrome coronavirus 
(MERS-CoV) infections in humans. Countries where human MERS-CoV infections have 
been identified are shown in tan. Numbers indicate the cumulative number of human 






Figure 1.4 Proposed transmission cycles for MERS-CoV. It is thought that MERS-CoV 
is transmitted either from bats to humans, although contact between these species is often 
limited, or from bats to dromedary camels to humans. Transmission between dromedary 
camels and humans may occur when humans come into close contact with infected camel 
respiratory tract secretions or through ingestion of unpasteurized camel milk containing 
MERS-CoV. Human-to-human transmission likely occurs through close contact with 
human respiratory tract secretions containing MERS-CoV. 
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Nipah virus is a paramyxovirus in the genus Henipavirus, which has caused 
outbreaks in humans in Malaysia, India, Singapore and Bangladesh. Whereas the human 
cases in Malaysia were characterized mainly by neurological symptoms and a case 
fatality rate of ~40%, cases in Bangladesh also exhibited respiratory disease and had a 
case fatality rate of ~70%. Here, we compared the histopathologic changes in the 
respiratory tract of Syrian hamsters, a well-established small animal disease model for 
Nipah virus, inoculated oronasally with Nipah virus isolates from human cases in 
Malaysia and Bangladesh. The Nipah virus isolate from Bangladesh caused slightly more 
severe rhinitis and bronchointerstitial pneumonia 2 days after inoculation in Syrian 
hamsters. By day 4, differences in lesion severity could no longer be detected. 
Immunohistochemistry demonstrated Nipah virus antigen in nasal cavity and pulmonary 
lesions; the amount of Nipah virus antigen present correlated with lesion severity. 
Immunohistochemistry indicated that both Nipah virus isolates exhibited 
endotheliotropism in small- and medium-caliber arteries and arterioles, but not in veins, 
in the lung. This correlated with the location of ephrin B2, the main receptor for Nipah 
virus, in the vasculature. In conclusion, Nipah virus isolates from outbreaks in Malaysia 
and Bangladesh caused a similar type and severity of respiratory tract lesions in Syrian 
hamsters, suggesting that the differences in human disease reported in the outbreaks in 
Malaysia and Bangladesh are unlikely to have been caused by intrinsic differences in 





Nipah virus is a paramyxovirus in the genus Henipavirus. Nipah virus was first 
identified in an outbreak in 1998 to 1999 in Malaysia, where it caused encephalitis and 
respiratory signs in pigs and encephalitis in humans who had contact with infected pigs.3,5  
Since 2001, Nipah virus has caused outbreaks in humans in Bangladesh almost every 
year. Whereas the initial outbreak in humans in Malaysia and Singapore was 
characterized mainly by neurological symptoms with occasional respiratory symptoms 
and a case fatality rate of approximately 40%,3 human cases in Bangladesh exhibited 
respiratory as well as neurological disease with a case fatality rate up to 92% in 
individual outbreaks.15 The main histologic changes in humans infected with Nipah virus 
in Malaysia were multiorgan vasculitis, fibrin thrombi, fibrinoid necrosis and occasional 
endothelial syncytia; vascular lesions were often associated with parenchymal necrosis 
and hemorrhage, especially in the brain with lesser involvement of the lung.20 In the 
Malaysia outbreak, Nipah virus was transmitted from its natural reservoir, Pteropus spp 
fruit bats, to pigs. It is suspected that pigs were infected by ingesting fruit contaminated 
with urine, feces or saliva from Nipah virus-infected fruit bats.14 Pigs acted as an 
intermediate, amplifying host for Nipah virus and transmitted this virus to humans 
through direct contact.4,16 Histologic lesions in Nipah virus-infected individuals from 
Bangladesh have not been described; however, the Bangladesh isolate has been reported 
to cause clinical symptoms similar to those in the Malaysia outbreak with the addition of 
acute respiratory distress syndrome.13 In the outbreaks in Bangladesh, epidemiologic 
studies suggest that Nipah virus was transmitted from fruit bats to humans through 




feces.15 Infected humans then transmitted the virus to other humans, likely through close 
contact with respiratory tract secretions.11 Nipah virus isolates from Malaysia and 
Bangladesh have been shown to share a sequence identity of 91.8% on the nucleotide 
level and >92% on the amino acid level.12  
Comparisons of a Nipah virus isolate from Malaysia to a Nipah virus isolate from 
Bangladesh in oronasally inoculated ferrets and intraperitoneally inoculated hamsters 
have been reported. Clayton et al6 showed that ferrets inoculated oronasally with either 
Nipah virus isolate developed similar clinical signs and multisystemic inflammation with 
vasculitis, yet ferrets inoculated with the Nipah virus isolate from Malaysia occasionally 
developed meningitis, while those inoculated with the Bangladesh isolate did not. 
Intraperitoneal inoculation of Syrian hamsters with either the Nipah virus isolate from 
Malaysia or Bangladesh resulted in similar histologic lesions, although the lesions 
developed more rapidly in hamsters inoculated with the Nipah virus isolate from 
Malaysia.9  
Here, we compare histologic lesions in the respiratory tract of Syrian hamsters 
oronasally inoculated with 107 TCID50 (50% tissue culture infectious dose) of a Nipah 
virus isolate from Malaysia (NiV-M) or Bangladesh (NiV-B). Although a previous study 
compared lesions caused by intraperitoneal inoculation of NiV-M or NiV-B in hamsters, 
this inoculation route may not accurately represent natural disease progression in humans. 
In our study comparing oronasally inoculated hamsters, differences in the severity of 
respiratory tract lesions in hamsters caused by NiV-B and NiV-M were minimal and only 





2.3 Materials and Methods 
 
2.3.1 Ethics Statement 
All animal experiments were approved by the Institutional Animal Care and Use 
Committee of the Rocky Mountain Laboratories and performed following the guidelines 
of the Association for Assessment and Accreditation of Laboratory Animal Care 
International (AAALAC) by certified staff in an AAALAC-approved facility. 
 
2.3.2 Case Selection and Histology 
Archived microscope slides from 6- to 8-week-old female Syrian hamsters 
(HsdHan:AURA; Harlan Laboratories, Indianapolis, Indiana), from previously published 
studies,7,8 euthanized 2 or 4 days after oronasal inoculation with 107 TCID50 NiV-M or 
NiV-B in a total volume of 100 µl or 80 µl respectively (50 or 40 µl/nostril) were 
analyzed histologically. Slides were originally prepared as 5-µm-thick sections of 
formalin-fixed, paraffin-embedded tissues adhered to microscope slides and then stained 
with hematoxylin and eosin or Verhoeff-Van Gieson stain. The Nipah virus isolates from 
Malaysia and Bangladesh were kindly provided by the Special Pathogens Branch of the 
Centers for Disease Control and Prevention (Atlanta, GA). NiV-M was isolated from the 
cerebrum of an infected fatal human case in 1999. NiV-B was isolated from a throat swab 
collected from a fatal human case in 2004.  
In the archived Nipah virus microscope slides, 5 hamsters inoculated were 
inoculated with NiV-M; 3 of these hamsters were euthanized at 2 dpi (case Nos. 1M-3M) 




inoculated with NiV-B; 4 hamsters each were euthanized at 2 dpi (case Nos. 6B-9B) and 
4 dpi (case Nos. 10B-13B). Examined tissues included the lung, nasal cavity (transverse 
or mid-sagittal sections through the skull) and brain. All tissues were analyzed for the 
presence of lesions and scored in a non-masked manner by two pathologists (L.B., 
D.P.S.). Any discrepancies in scoring values were discussed and a final score was 
mutually agreed on by the pathologists. Lesion severity was scored as follows: 0 = the 
lesion was absent, 1 = up to 25% of the described tissue or cell type was affected, 2 = up 
to 50% of the described tissue or cell type was affected, 3 = up to 75% of the described 
tissue or cell type was affected, and 4 = 75% to 100% of the described tissue or cell type 
was affected.  
 
2.3.3 Immunohistochemistry 
Immunohistochemistry was performed on all tissues examined histologically 
using a rabbit polyclonal antiserum against the Nipah virus nucleoprotein2 (1:5000; 
kindly provided by L. Wang, CSIRO Livestock Industries, Australian Animal Health 
Laboratory, Geelong, Victoria, Australia) as a primary antibody for detection of Nipah 
virus antigen. The tissues were then processed for immunohistochemistry using the 
Discovery XT automated processor (Ventana Medical Systems, Tucson, AZ) with a DAB 
Map kit (Ventana Medical Systems). All tissues were scored based on the percentage of 
the tissue that was immunopositive for Nipah virus nucleoprotein: 0 = negative, 1 = up to 
25% of the tissue was immunopositive, 2 = up to 50% of the tissue was immunopositive, 
3 = up to 75% of the tissue was immunopositive, 4 = 75% to 100% of the tissue was 




(L.B., D.P.S.); any discrepancies in scoring values were discussed and a final score was 
mutually agreed upon by the pathologists. 
 
2.3.4 Statistical Analysis 
A Fisher’s exact test was performed using GraphPad (Prism version 6.02 for 
Windows, GraphPad Software, La Jolla, CA) to determine statistical significance 
between the scoring values of animals inoculated with NiV-B or NiV-M at each time 
point and for the presence or absence of Nipah virus nucleoprotein in arteries or veins in 




2.4.1 Nasal Cavity 
 In the nasal cavity, the histologic differences between hamsters inoculated with 
NiV-B and NiV-M were minimal and observed on day 2 only (Table 2.1). Differences in 
lesion severity were seen in the submucosal glands and respiratory and olfactory 
epithelium. Submucosal gland epithelial degeneration on 2 dpi was present only in 
hamsters inoculated with NiV-B. NiV-B caused slightly more severe olfactory epithelial 
lesions than NiV-M 2 dpi, whereas NiV-M caused slightly more severe respiratory 
epithelial lesions. Both Nipah virus isolates caused mild neutrophilic rhinitis with 
respiratory and olfactory epithelial degeneration, necrosis and syncytia formation (Figure 
2.1 A, B). Rhinitis caused by NiV-B was multifocal to coalescing and affected up to 10% 




or less of the nasal cavity. Nasal cavity lesions were more severe at 4 dpi than at 2 dpi for 
both NiV-B and NiV-M. Lesion severity and distribution were similar at 4 dpi for both 
virus isolates (Figure 2.1 C, D; Table 2.2), with up to 50% of the nasal cavity being filled 
with inflammatory infiltrate. Multifocal to coalescing ulcers and submucosal gland 
epithelial degeneration, necrosis and syncytia were present. Prominent vascular lesions 
were observed at 4 dpi, including fibrinoid degeneration and fibrin thrombi in multiple 
nasal submucosal small- and medium-caliber vessels. 
Nipah virus antigen was detected in the same cell types in hamsters inoculated 
with either NiV-M or NiV-B and antigen was more abundant at 4 dpi compared to 2 dpi 
(Table 2.3). Multifocally, Nipah virus antigen was present in the cytoplasm of nasal 
cavity olfactory, respiratory and submucosal gland acinar epithelium, mononuclear 
leukocytes and neutrophils (Figure 2.2 A-D). Nipah virus antigen was also present in the 
cytoplasm of endothelial cells in small- to medium-caliber vessels in the nasal submucosa 
in all hamsters inoculated with NiV-M at 4 dpi, but was not present at 2 dpi. In hamsters 
inoculated with NiV-B, 1 out of 4 hamsters (25%) at 2 dpi and 3 out of 4 hamsters (75%) 
at 4 dpi expressed Nipah virus antigen in endothelial cells.  
The only statistically significant difference (P < .03) between NiV-M and NiV-B 
in the nasal cavity was the presence of submucosal gland epithelial degeneration in 







 Differences in lesion severity caused by NiV-B and NiV-M were minor and noted 
only at 2 dpi, and involved the extent of the bronchointerstitial pneumonia (Table 2.1) 
and formation of bronchiolar epithelial syncytia. Both Nipah virus isolates caused a 
multifocally distributed bronchointerstitial pneumonia centered on terminal bronchioles 
with scattered fibrin thrombi in alveolar septal capillaries in all hamsters at 2 dpi. NiV-B 
caused more extensive bronchointerstitial pneumonia at 2 dpi than NiV-M, affecting up 
to 50% of the lung as compared with less than 25% of the lung, respectively (Figure 2.3 
A, B). Multiple small- and medium-caliber blood vessels in the lung exhibited vasculitis 
with disruption of the vascular wall and rare endothelial syncytia in hamsters inoculated 
with either virus isolate. Bronchiolar epithelial syncytia were seen at 2 dpi in all hamsters 
inoculated with NiV-M, but were present only in 1 of 4 hamsters inoculated with NiV-B. 
At 4 dpi, bronchiolar epithelial syncytia were present in 1 of 2 hamsters inoculated with 
NiV-M and 1 of 4 hamsters inoculated with NiV-B. At 4 dpi the bronchointerstitial 
pneumonia caused by NiV-B and NiV-M had a similar distribution and severity (Table 
2.2), was more extensive than at 2 dpi, affected up to 75% of the lung, and exhibited 
multifocal type II pneumocyte hyperplasia (Figure 2.3 C, D).  
In the lung, the location of Nipah virus antigen was similar for both NiV-B and 
NiV-M (Figure 2.4 A-D) and the amount of antigen present for both virus isolates 
increased from 2 dpi to 4 dpi (Table 2.3). Nipah virus antigen was detected in the 
cytoplasm of multiple alveolar septal capillary endothelial cells, type I pneumocytes, and 
mononuclear leukocytes at 2 dpi in all hamsters. Nipah virus antigen was present in 




NiV-M (case No. 2M) and 1 hamster inoculated with NiV-B (case No. 9B). At 4 dpi, 
Nipah virus antigen was also present in scattered type II pneumocytes, endothelial cells, 
and vascular smooth muscle cells in hamsters inoculated with either NiV-B or NiV-M.  
 
2.4.3 Pulmonary Vasculature 
 Nipah virus antigen was present in endothelial and smooth muscle cells in 
multiple small- and medium-caliber blood vessels at 4 dpi in the lung of hamsters 
inoculated with either NiV-B or NiV-M. Through the comparison of hematoxylin and 
eosin (HE) and Nipah virus antigen immunohistochemistry on sequential sections of 
lung, it appeared that Nipah virus antigen had a tropism for arteries rather than veins. 
Since it can be difficult to differentiate small- and medium-caliber arteries and veins in 
the lung on HE, a Verhoeff-Van Gieson stain was performed on sections of lung to 
identify the presence or absence of internal and external elastic laminae in blood vessels. 
A comparison of HE, Verhoeff-Van Gieson and immunohistochemistry using anti-Nipah 
virus nucleoprotein antibody on serial sections of the lung was performed on all hamsters 
inoculated with either NiV-B or NiV-M that were euthanized at 4 dpi to elucidate if there 
was an arterial tropism. Ten arteries and ten veins were analyzed in each hamster. 
Multiple small-caliber blood vessels were not included in the analysis since their scanty 
tunica media made it difficult to discern if there was 1 lamina or 2 laminae that were 
barely separated by a thin tunica media. In each hamster, the endothelium of at least 5 of 
10 arteries examined contained Nipah virus nucleoprotein (Figure 2.5 A-C), whereas 
none of the veins did (Figure 2.5 D-F). This arterial tropism was observed in hamsters 








 Lesions were not present in the brain in any hamster inoculated with either Nipah 
virus isolate. Nipah virus antigen was not observed in the brain parenchyma in any 
hamster at either 2 dpi or 4 dpi. 
 
2.5 Discussion 
Syrian hamsters were used as an animal model to investigate histopathologic 
differences between NiV-M and NiV-B since they recapitulate the disease caused by 
Nipah virus in humans.7,9,17,19 In Nipah virus-infected hamsters, clinical signs and 
histologic lesions depend on the infectious dose and route of inoculation. Hamsters 
oronasally inoculated with a high dose of Nipah virus develop acute severe respiratory 
disease, while low doses initially cause mild respiratory disease and then subsequent 
neurological signs.17 High doses of NiV-B or NiV-M have both been shown to be 
uniformly lethal in oronasally inoculated hamsters.7,8 In this study, all hamsters were 
inoculated with a high dose of either NiV-B or NiV-M to evaluate the respiratory 
component of these diseases. At the time points that were examined, Nipah virus antigen 
had not yet disseminated to the brain, as determined by immunohistochemistry, and 
lesions were not present in this tissue. Oronasal inoculation of hamsters with NiV-B or 
NiV-M resulted in subtle differences in lesion severity in the respiratory tract at 2 dpi, 




Immunohistochemistry for Nipah virus antigen in the nasal cavity 2 days after oronasal 
inoculation with NiV-M or NiV-B in Syrian hamsters showed that a higher percentage of 
epithelial cells in the nasal cavity contained Nipah virus antigen in hamsters inoculated 
with NiV-B. Although this may have been due to the different inoculum volumes used, it 
could also indicate that NiV-B entry into epithelial cells lining the nasal cavity is more 
rapid than NiV-M entry into cells or that NiV-B replicates faster within epithelial cells 
than NiV-M. This is one scenario that may also explain the observed lesions in the 
submucosal gland epithelium in NiV-B infected hamsters on 2 dpi, as a faster replication 
rate may have resulted in a faster progression to infection of this deeper-lying tissue.  
On 2 dpi, NiV-B showed a slight predilection for damaging olfactory epithelium 
and NiV-M exhibited a slight predilection for damaging respiratory epithelium in 
oronasally infected hamsters. The exact mechanism behind these predilections is 
unknown, but could possibly be due to genetic differences resulting in phenotypic 
variation in the glycoproteins G and F between these two isolates12 which may affect cell 
entry of these viruses through host receptor binding on olfactory or respiratory 
epithelium. In addition, a combination of viral genetic differences and variations in 
cellular structure and function between respiratory and olfactory epithelium may have 
caused differences in the viral replication rates in these two epithelial cell types. 
By 4 dpi, the type and severity of lesions in the lung and nasal cavity was similar 
for both Nipah virus isolates. Although disease progression was initially more rapid for 
NiV-B, by 4 dpi both Nipah virus isolates caused essentially the same severity of 
pulmonary and nasal cavity lesions in Syrian hamsters. Similarly, in ferrets oronasally 




histologic lesions were comparable.6 Intraperitoneal inoculation of Syrian hamsters with 
NiV-B or NiV-M also did not result in differences in lesion severity between the 2 
isolates, although disease onset and lesion development were faster with NiV-M than 
NiV-B.9 However, all studies to date comparing NiV-M and NiV-B have used the same 2 
isolates and the results would be strengthened if these studies could be repeated using 
virus isolates from different outbreaks in Bangladesh.  
To our knowledge, this is the first study that describes the tropism of Nipah virus 
for endothelium within arteries and arterioles, but not veins. Other studies have examined 
the presence of Nipah virus antigen within blood vessels, but have not exclusively 
localized antigen to endothelium in arteries and arterioles rather than veins.10,20 This 
tropism correlates with the expression of ephrin B2, the main receptor for Nipah virus, in 
arterial but not venous endothelium; venous endothelium typically expresses Eph-B418 
which is not a receptor for Nipah virus. 
Taken together, the results presented here do not explain the increased case 
fatality rate seen in humans infected with NiV-B; rather, the results suggest that 
differences between the outbreaks in Malaysia and Bangladesh were not caused by 
intrinsic differences between NiV-B and NiV-M. Other factors, such as the route of 
infection or dose of the virus received, which were identical in hamsters inoculated with 
either NiV-B or NiV-M in this study, may have played a role in the differences in disease 
outcome in infected humans in Malaysia and Bangladesh. For instance, in the Malaysia 
outbreak, humans were exposed to the virus through close contact with pigs,16 whereas in 
the Bangladesh outbreaks, humans were thought to be infected by drinking Nipah virus-




infected humans.11,15 In addition, differences in the availability of health care facilities, 
willingness to seek medical care early in the infection, the role that family members play 
in caring for the ill or other cultural differences may play a role in the differences noted 
between the outbreaks in Malaysia and Bangladesh in humans.  
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Table 2.1 Histologic severity of respiratory tract lesions in Syrian hamsters inoculated 










Acinar Deg./ Necrosis 
Bronchointerstitial 
Pneumonia 
1M/Mal 1 1/1 1/1 0/0 1 
2M/Mal 1 2/0 1/1 0/0 1 
3M/Mal 1 2/2 0/0 0/0 1 
6B/Bang 1 1/0 1/1 1/0 2 
7B/Bang 1 3/1 1/1 1/0 2 
8B/Bang 1 1/0 1/1 1/0 1 
9B/Bang 1 1/0 2/1 1/0 2 
 
Mal, Nipah virus isolate from Malaysia; Bang, Nipah virus isolate from Bangladesh; Epi., 
Epithelial; Deg., Degeneration. 
 
Tissues from the nasal cavity (respiratory epithelium, olfactory epithelium and 
submucosal glands) and lung (bronchointerstitial pneumonia) were scored. Scoring 
protocol: 0 = no lesions; 1 = up to 25% of the described tissue or cell type affected; 2 = 
up to 50% of the described tissue or cell type affected; 3 = up to 75% of the described 








Table 2.2 Histologic severity of respiratory tract lesions in Syrian hamsters inoculated 










Acinar Deg./ Necrosis 
Bronchointerstitial 
Pneumonia 
4M/Mal 2 2/1 2/1 1/1 3 
5M/Mal 2 3/1 1/2 1/2 1 
10B/Bang 1 1/1 1/0 1/0 3 
11B/Bang 2 0/0 2/2 2/1 2 
12B/Bang 1 1/0 1/2 1/1 3 
13B/Bang 2 1/1 2/2 2/2 2 
 
Mal, Nipah virus isolate from Malaysia; Bang, Nipah virus isolate from Bangladesh; Epi., 
Epithelial; Deg., Degeneration. 
 
Tissues from the nasal cavity (respiratory epithelium, olfactory epithelium and 
submucosal glands) and lung (bronchointerstitial pneumonia) were scored. Scoring 
protocol: 0 = no lesions; 1 = up to 25% of the described tissue or cell type affected; 2 = 
up to 50% of the described tissue or cell type affected; 3 = up to 75% of the described 










Table 2.3 Immunohistochemistry scoring for Nipah virus nucleoprotein in the respiratory 
tract of Syrian hamsters inoculated with either a Nipah virus isolate from Malaysia or 
Bangladesh 
 
Hamster No. Isolate Necropsy, Dpi Nasal Cavity Lung 
1M Mal 2 1 2 
2M Mal 2 1 2 
3M Mal 2 1 2 
4M Mal 4 2 3 
5M Mal 4 3 1 
6B Bang 2 2 2 
7B Bang 2 2 3 
8B Bang 2 2 2 
9B Bang 2 2 2 
10B Bang 4 1 3 
11B Bang 4 3 3 
12B Bang 4 2 2 
13B Bang 4 2 2 
 
Dpi, days post inoculation; Mal, Nipah virus isolate from Malaysia; Bang, Nipah virus 
isolate from Bangladesh. 
 
Scoring protocol: 0 = negative, 1 = up to 25% of the tissue was immunopositive; 2 = up 
to 50% of the tissue was immunopositive; 3 = up to 75% of the tissue was 









Figure 2.1 Infection with a Nipah virus isolate from Malaysia (NiV-M) or Bangladesh 
(NiV-B), Syrian hamster, nasal cavity. HE. A. Rhinitis with olfactory epithelial 
degeneration and necrosis and multifocal erosions (arrows; inset) 2 days post inoculation 
(dpi) with NiV-M. B. Rhinitis with olfactory epithelial degeneration and necrosis 
(arrows; inset) 2 dpi with NiV-B. C. Rhinitis with multifocal ulcers (asterisk) and 
submucosal vascular fibrinoid degeneration (arrow; inset) 4 dpi with NiV-M. D. Rhinitis 
affecting olfactory epithelium (asterisk) and respiratory epithelium (arrowhead) with 






Figure 2.2 Infection with a Nipah virus isolate from Malaysia (NiV-M) or Bangladesh 
(NiV-B), Syrian hamster, nasal cavity. IHC for Nipah virus nucleoprotein. A. 
Cytoplasmic expression of viral antigen in olfactory epithelium (arrow) 2 days post 
inoculation (dpi) with NiV-M. B. Cytoplasmic expression of viral antigen in olfactory 
(arrow) and submucosal gland acinar epithelium (arrowhead) 2 dpi with NiV-B. C. 
Cytoplasmic expression of viral antigen in olfactory (arrow) and submucosal gland acinar 
epithelium (arrowhead) 4 dpi with NiV-M. D. Cytoplasmic expression of viral antigen in 







Figure 2.3 NiV-M or NiV-B infection, Syrian hamster, lung. HE. A. Bronchointerstitial 
pneumonia with bronchiolar epithelial syncytium (arrow; inset) 2 dpi with NiV-M. B. 
Bronchointerstitial pneumonia 2 dpi with NiV-B. Inset: higher magnification of 
pneumonia. C. Bronchointerstitial pneumonia with type II pneumocyte hyperplasia 
(arrow; inset) 4 dpi with NiV-M. D. Bronchointerstitial pneumonia with type II 







Figure 2.4 NiV-M or NiV-B infection, Syrian hamster, lung. IHC for Nipah virus 
nucleoprotein. A. Cytoplasmic expression of viral antigen in type I pneumocytes (arrow) 
and bronchiolar epithelium (arrowhead) 2 dpi with NiV-M. B. Cytoplasmic expression of 
viral antigen in type I pneumocytes (arrow) 2 dpi with NiV-B. C. Cytoplasmic expression 
of viral antigen in type I (black arrow) and type II pneumocytes (arrowhead) and 
mononuclear leukocytes (white arrow) 4 dpi with NiV-M. D. Cytoplasmic expression of 
viral antigen in type I (black arrow) and type II pneumocytes (arrowhead) and 






Figure 2.5 A-C. Nipah virus infection, Syrian hamster, serial sections of an artery in the 
lung. A. The tunica adventitia is expanded by edema and a mild infiltrate of neutrophils, 
lymphocytes and macrophages (asterisk; inset). HE. B. Cytoplasmic expression of Nipah 
virus nucleoprotein in arterial endothelial cells (arrow), smooth muscle cells in the tunica 
media (asterisk) and perivascular leukocytes (arrowhead). Inset: higher magnification of 
viral antigen expression. Nipah virus nucleoprotein IHC. C. Internal (arrowhead) and 
external (arrow) elastic laminae are prominent in this vessel, indicating the vessel is a 
pulmonary artery. Inset: higher magnification of vascular elastic laminae. Verhoeff-Van 
Gieson stain. D-F. Nipah virus infection, Syrian hamster, serial sections of a vein in the 
lung. D. The tunica adventitia is expanded by an infiltrate of neutrophils and 
macrophages with fewer lymphocytes and plasma cells (asterisk; inset). HE. E. 
Cytoplasmic expression of Nipah virus nucleoprotein in perivascular leukocytes (arrow; 
inset). Nipah virus antigen was not present in endothelial cells. Nipah virus nucleoprotein 
IHC. F. The vessel exhibits an incomplete internal elastic lamina (arrow; high-power 
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In humans, Nipah virus causes respiratory disease and neurologic symptoms. In 
fatal human Nipah virus infections, lesions have been described in the respiratory and 
nervous systems, vasculature and lymphoid organs; cellular damage was reported in 
epithelial cells, endothelial cells and neurons. However, since the reported data are from 
the late stages of disease, the progression of Nipah virus infection through the different 
target organs and cells during the early phase of disease remains poorly understood. Here, 
we tracked Nipah virus dissemination during the early phase of infection in intranasally 
inoculated Syrian hamsters with either a Nipah virus isolate from Malaysia (NiV-M) or 
Bangladesh (NiV-B). Nipah virus initially targeted the lung and nasal cavity. Virus 
replication was identified at 8 hours post inoculation (hpi) in type I pneumocytes, 
bronchiolar respiratory epithelium and alveolar macrophages. Viral spread to bronchiolar 
smooth muscle and arterial smooth muscle in the lung was first detected at 16 hpi and 32 
hpi, respectively. In the nasal cavity, respiratory and olfactory epithelium were initially 
targeted, followed by spread to underlying submucosal gland acinar epithelium. Virus 
appeared to spread from the lung and/or nasal cavity to the larynx and trachea. The 
pattern of viral dissemination was similar in NiV-M and NiV-B inoculated hamsters; 
however, dissemination was slower for NiV-B. In hamsters inoculated with either virus 
isolate, even at 48 hpi we did not detect infectious virus in the central nervous system or 
viral infection of blood vessels in multiple organs. These results suggest that virus 
replication in the brain and viral infection of blood vessels in non-respiratory tract tissues 
does not occur during the early phase of infection and may be prevented by rapid 





Nipah virus is a highly virulent, zoonotic paramyxovirus that was first identified 
in an outbreak that affected pigs and humans in Malaysia and Singapore in 1998-1999.5,21 
Subsequently, Nipah virus has caused almost yearly outbreaks in humans in 
Bangladesh.13,14,16,22 Humans infected during the initial outbreak in Malaysia mainly 
exhibited neurologic symptoms while some also developed respiratory disease; the case 
fatality rate was approximately 40%.4,10,20,30 Outbreaks in Bangladesh have resulted in 
neurologic disease, a higher incidence of respiratory disease, limited human-to-human 
transmission and case fatality rates up to 100%.12,14,24,28 Histologic lesions have only been 
described in fatal human cases from the Malaysia outbreak and were characterized by 
systemic vascular damage often associated with infarcts in the central nervous system and 
lung.5,10,30 Tissues analyzed from fatal human Nipah virus infections depicted signs of 
cellular damage in endothelial cells, neurons and epithelial cells.30 Additionally, in a few 
of the fatal human cases, lesions were reported in lymphoid organs, including the spleen, 
which exhibited white pulp lymphoid depletion, and lymph nodes.30 These findings show 
that the vasculature and the respiratory, nervous and immune systems are infected by 
Nipah virus. However, since the reported data are from the late stages of disease, the 
progression of Nipah virus infection through the different target organs remains poorly 
defined. Understanding the initial organ and cell types a virus targets is a vital first step 
towards determining the most effective route and time frame for administering antivirals 





Several animal models of Nipah virus infection have been developed, including 
the Syrian hamster model which recapitulates several aspects of human Nipah virus 
disease. Syrian hamsters experimentally inoculated with Nipah virus have been shown to 
develop late stage lesions similar to those in humans, including vascular disease and 
lesions in the respiratory and nervous systems, with rare involvement of the spleen.2,7-
9,19,23,29 Thus, the Syrian hamster model likely mimics the early pathogenesis of Nipah 
virus infection in humans and could be used to study the early target cells of Nipah virus 
infection and viral spread to subsequent cells and organ systems. Although the route of 
systemic virus dissemination is unclear, it is suspected that lymphocytes may play a role. 
It has been shown that Nipah virus can bind to human lymphocytes and hamster 
mononuclear leukocytes and that these leukocytes can carry and transfer the virus to 
permissive cells.17 As such, lymphocytes may transfer virus to endothelial cells in blood 
vessels throughout the body, which could cause systemic virus dissemination, potentially 
followed by viral spread from blood vessels to adjacent parenchymal cells, including 
epithelial cells and neurons.27 These lymphocytes can also transmigrate through vascular 
walls in tissues and directly transfer Nipah virus to underlying permissive parenchymal 
cells, including epithelial cells and neurons. Epithelial cells lining the respiratory tract 
may not only become infected via a hematogenous route, but they can also be exposed to 
Nipah virus through inhalation of viral particles. Neurons in the brain may also become 
infected if Nipah virus spreads from olfactory neurons in the nasal cavity to the olfactory 
nerve, which leads to the olfactory bulb of the brain.19, 27 Once in the olfactory bulb, 




cord. Regardless of the route of virus dissemination, the end result is often development 
of severe clinical disease and potentially death.  
Here, we identified the initial target cell types and organs during the first 48 hours 
of Nipah virus infection upon intranasal inoculation of Syrian hamsters. We showed that 
the lung and nasal cavity are the initial target organs and that Nipah virus replication can 
be identified at 8 hours post inoculation in type I pneumocytes, bronchiolar respiratory 
epithelial cells and alveolar macrophages at this time point. In the nasal cavity, 
respiratory and olfactory epithelium are the initial targets. Virus then appears to 
disseminate to the trachea and larynx. We did not detect infectious virus or virus 
replication in the central nervous system or viral infection of multisystemic blood vessels, 
even at 48 hours post inoculation, suggesting these are not early events.  
 
3.3 Materials and Methods 
 
3.3.1 Ethics Statement 
All animal experiments were approved by the Institutional Animal Care and Use 
Committee of the Rocky Mountain Laboratories and performed following the guidelines 
of the Association for Assessment and Accreditation of Laboratory Animal Care 
International (AAALAC) by certified staff in an AAALAC-approved facility. 
 
3.3.2 Virus and Cells 
Nipah virus isolates from Bangladesh (NiV-B) and Malaysia (NiV-M) were 




Prevention, Atlanta, Georgia, United States. NiV-B was isolated from a throat swab 
collected from a fatal human case in 2004. NiV-M was isolated from the cerebrum of a 
fatal human case in 1999. 
 
3.3.3 Animal Experiments 
Two groups of twenty-four 6- to 8-week-old female Syrian hamsters 
(HsdHan:AURA; Harlan Laboratories, Haslett, MI) were intranasally inoculated with 5 x 
106 TCID50 (50% tissue culture infectious dose) of either NiV-B or NiV-M in a total 
volume of 80 µl (40 µl per nostril). All hamsters were evaluated daily for clinical signs of 
disease, including weight loss. Four hamsters from each group were euthanized at 4, 8, 16, 
24, 32 and 48 hours post inoculation (hpi). A terminal heart blood sample was collected 
from each hamster before necropsy. Nasal turbinates, larynx, trachea, lung, cervical 
lymph nodes, spleen, brain and thoracolumbar spinal cord were collected for histologic 
and virologic analysis. 
 
3.3.4 Histology, Immunohistochemistry and In Situ Hybridization 
Necropsies and tissue sampling were performed according to a standard protocol 
approved by the Institutional Biosafety Committee. Tissues were fixed for a minimum of 
7 days in 10% neutral-buffered formalin and embedded in paraffin. The sections of nasal 
turbinates, contained within the skull, and spinal cord, contained within the vertebrae, 
were decalcified using a 20% EDTA solution in sucrose prior to paraffin embedding.  
Leukocytes were isolated from terminal blood samples using centrifugation over a 




(Life Technologies) according to manufacturer instructions. The resulting leukocyte 
pellets were fixed for a minimum of 24 hours in 10% neutral-buffered formalin. 
Leukocytes from hamsters inoculated with the same Nipah virus isolate and which were 
euthanized at the same time point were pooled, then processed in HistoGel (Thermo 
Scientific) according to manufacturer instructions and embedded in paraffin to form a cell 
block. 
Routine hematoxylin and eosin (H&E) staining, immunohistochemisy (IHC) and 
in situ hybridization (ISH) were performed on tissue sections and cell blocks. Nipah virus 
antigen was detected by IHC; tissue sections were labeled with a rabbit polyclonal 
antiserum against Nipah virus nucleoprotein (1:5000; kindly provided by L. Wang, 
CSIRO Livestock Industries, Australian Animal Health Laboratory, Australia).3 Nipah 
virus replication was detected in tissue sections by ISH using probes specific for positive 
sense Nipah virus nucleoprotein RNA; the method used here has been previously 
described.26 All slides were evaluated by a board certified veterinary anatomic 
pathologist. 
 
3.3.5 Quantitative Real-Time RT-PCR (qRT-PCR) 
Viral RNA was isolated from hamster tissues using the RNeasy Mini kit (Qiagen) 
or from hamster blood using the QIAamp Viral RNA Mini kit (Qiagen), according to the 
instructions of the manufacturer. 5 µl of RNA was used in a one-step real-time RT-PCR 
targeting the Nipah virus nucleoprotein, as described previously,8 using the QuantiFast 




of RNA extracted from a titered virus stock were run in parallel, to calculate TCID50 
equivalents in the samples. 
 
3.3.6 Virus Titrations 
Virus titrations were performed by end-point titration in Vero C1008 cells. Vero 
C1008 cells were inoculated with tenfold serial dilutions of tissue homogenates. One 
hour after inoculation of cells with tissue homogenates, the inoculum was removed and 
replaced with 200 µl DMEM supplemented with 2% fetal bovine serum, 1 mM L-
glutamine, 50 U/ml penicillin and 50 µg/ml streptomycin. Five days after inoculation 
with tissue homogenates from NiV-B inoculated hamsters and three days after 
inoculation with tissue homogenates from NiV-M inoculated hamsters, cytopathic effect 





3.4.1 Nipah Virus Replication is Detected at 8 Hours Post Inoculation 
In hamsters inoculated intranasally with 5 x 106 TCID50 of NiV-M, viral RNA 
was detected by qRT-PCR at 4 hpi in the lung, nasal turbinates, trachea, larynx, cervical 
lymph nodes and brain (Figure 3.1). Although viral RNA was found as early as 4 hpi in 
several respiratory tract tissues, infectious virus was isolated at 8 hpi in the lung and nasal 
turbinates and not until 16 hpi in the trachea and larynx (Figure 3.2). In situ hybridization 




which is only observed when virus replication occurs, first detected virus replication at 8 
hpi in the lung and 16 hpi in the nasal turbinates in 2 out of 4 hamsters at each time point 
(Tables 3.1 and 3.2, Figure 3.3). The lack of positive sense viral RNA at 4 hpi in all of 
the tissues, in addition to the decrease in detected viral loads in most tissues between 4 
hpi and 8 hpi, suggests that the viral RNA detected at 4 hpi by qRT-PCR represented the 
administered viral inoculum rather than virus replication. Thus, the first evidence of 
Nipah virus replication was detected at 8 hpi. 
 
3.4.2 Nipah Virus Initially Targets the Lung and Nasal Cavity 
In hamsters inoculated intranasally with NiV-M, positive sense viral RNA, 
indicating virus replication, was detected in type I pneumocytes and bronchiolar 
respiratory epithelium at 8 hpi in 2 out of 4 hamsters (Table 3.1). Additionally, positive 
sense viral RNA was also detected in alveolar macrophages in 2 out of 4 hamsters at 8 
hpi. Starting at 16 hpi, virus replication was observed in respiratory epithelium lining 
bronchi in 2 out of 4 hamsters. Immunohistochemistry (IHC) that targeted the Nipah 
virus nucleoprotein antigen was used to track virus dissemination throughout the lung 
between 4 and 48 hpi; increasing amounts of viral antigen were detected at subsequent 
time points (Table 3.3, Figure 3.4). By 16 hpi, viral antigen had spread from alveoli and 
bronchioles to the larger airways and was found in the bronchial respiratory epithelium in 
2 out of 4 hamsters. In bronchioles, at 16 hpi viral antigen had spread from the 
bronchiolar epithelium to the underlying bronchiolar smooth muscle in 1 out of 4 
hamsters. Spread of viral antigen to arterial smooth muscle cells in the lung was only 




vessels. At both time points, vascular involvement was only observed in 1 out of 4 
hamsters and affected one to a few small-caliber arteries, but not veins. In the nasal 
cavity, infectious virus was detected at 8 hpi. Positive sense viral RNA, indicating virus 
replication had occurred, was observed in respiratory and olfactory epithelium at 16 hpi 
(Table 3.2). Tracking of viral antigen in the nasal cavity over time showed that 
respiratory and olfactory epithelium were infected first, followed by infection of the 
submucosal gland epithelium underlying both respiratory and olfactory epithelial cells at 
24 hpi (Table 3.4, Figure 3.4). Viral antigen was not observed in the vascular smooth 
muscle cells or endothelium in the nasal cavity at any time point. 
 
3.4.3 Nipah Virus Spreads from Nasal Cavity or Lung to Trachea and Larynx 
Although infectious virus was detected at 8 hpi in the lung and nasal cavity of 
hamsters intranasally inoculated with NiV-M, it was not until later time points that Nipah 
virus was detected in the trachea and larynx. At 16 hpi, positive sense viral RNA and 
Nipah virus antigen were identified in the trachea in 2 out of 4 hamsters (Figure 3.5). 
Additionally, infectious virus was isolated from the trachea and larynx at 16 hpi. 
However, IHC first detected viral antigen in the larynx at 32 hpi and positive sense viral 
RNA, as analyzed by ISH, was not identified in this tissue at any time point examined 
despite detection of infectious virus and viral RNA, by qRT-PCR (Figure 3.5). As ISH 
and IHC are evaluated histologically, it is possible that positive sense viral RNA and viral 
antigen may have also been present in the larynx at 16 hpi, but were not found in the 




viral RNA at 8 hpi in both of these tissues suggests that Nipah virus spreads from one or 
both of its initial target organs, the nasal cavity and lung, to the trachea and larynx.  
 
3.4.4 Nipah Virus Disseminates Outside of the Respiratory Tract 
Dissemination of Nipah virus through the vascular system was also analyzed. ISH 
and IHC were performed on cell blocks made up of peripheral leukocytes collected 
during terminal heart bleeds. Positive sense viral RNA and viral antigen were not 
observed in peripheral leukocytes at any time point. Additionally, viral RNA was not 
detected in the peripheral blood by qRT-PCR (data not shown). These results suggest that 
Nipah virus was either not bound to, or replicating in, leukocytes circulating in blood or 
levels of virus in the blood were below the limit of detection. Furthermore, even at 48 hpi, 
viral antigen and positive sense viral RNA were not detected in the vasculature of any 
organ examined, other than the lung. Additionally, lesions associated with Nipah virus 
infections of the vascular wall, including vasculitis, fibrinoid change and fibrin thrombi, 
were not detected histologically at any time point in any organ, except the lung. 
In hamsters intranasally inoculated with NiV-M, lymphoid organs were analyzed 
for signs of virus dissemination. Infectious virus was only detected at 48 hpi in the 
cervical lymph node in 2 out of 4 hamsters and in the spleen of 1 out of 4 hamsters; viral 
titers were low in these animals (Figure 3.2). Positive sense viral RNA and viral antigen 
were not detected in the lymphoid organs at any time point.  
The central nervous system was also analyzed for evidence of virus dissemination. 
Low viral loads were detected by qRT-PCR in a few hamsters in the brain and spinal cord 




RNA were identified in the central nervous system tissues at any time point (data not 
shown). These results suggest that during the first 48 hpi, Nipah virus was not yet 
replicating in the brain or spinal cord. 
 
3.4.5 NiV-B Mirrors the Early Target Cells of NIV-M yet Exhibits Slower Virus 
Dissemination  
  Since the human case fatality rates and prevalence of respiratory disease 
were different between Nipah virus outbreaks in Malaysia and Bangladesh,4,20,24,28 we 
sought to determine whether there were differences in the early pathogenesis of Nipah 
virus infections caused by either NiV-M or NiV-B. The same experimental protocols and 
analyses were performed on hamsters inoculated with either Nipah virus isolate.  
Similar to hamsters inoculated with NiV-M, viral RNA was detected by qRT-PCR 
in the respiratory and central nervous systems and cervical lymph nodes at 4 hpi in 
hamsters intranasally inoculated with NiV-B (Figure 3.6). Despite the detection of viral 
RNA in several tissues at 4 hpi, infectious virus and positive sense viral RNA were first 
detected at either 8 or 16 hpi and were only present in respiratory tract tissues (Figure 3.7 
and 3.8). Positive sense viral RNA, indicating virus replication, was detected by 8 hpi in 
type I pneumocytes and alveolar macrophages in 4 out of 4 hamsters and in bronchiolar 
respiratory epithelium in 2 out of 4 hamsters (Table 3.5, Figure 3.8). Similar to NiV-M 
inoculated hamsters, the respiratory and olfactory epithelium in the nasal cavity were also 
early target cells for virus replication, as observed by ISH (Table 3.6, Figure 3.8). The 
presence of Nipah virus antigen in the lung and nasal cavity, as detected by IHC, 




inoculated hamsters, dissemination of viral antigen to pulmonary bronchiolar and arterial 
smooth muscle cells was not observed, even at 48 hpi. Spread of viral antigen in the nasal 
cavity from the epithelial cells to the underlying submucosal glands took longer in NiV-B 
inoculated hamsters and was not detected until 48 hpi; viral antigen was first identified at 
24 hpi in NiV-M inoculated hamsters. Similar to NiV-M inoculated hamsters, Nipah 
virus appeared to spread from the nasal cavity or lung to the trachea and larynx (Figure 
3.10). Widespread vascular dissemination was not detected and infectious virus, viral 
antigen and virus replication were not identified in the brain, spinal cord or lymphoid 
organs at any time point in NiV-B inoculated hamsters. 
 
3.5 Discussion 
In this study, Syrian hamsters were intranasally inoculated with either NiV-M or 
NiV-B in order to evaluate the progression of Nipah virus dissemination during the early 
stage of infection and to pinpoint early Nipah virus target organs and cells. Identifying 
the initial viral target organ and cell types and the route of virus dissemination to 
subsequent tissues is vital for determining the most effective route and time frame for 
administering antivirals aimed at preventing systemic virus dissemination and severe 
disease. In our study, the lung and nasal cavity were identified as early Nipah virus 
targets in hamsters inoculated with either Nipah virus isolate. Virus replication was 
detected by ISH early in the infection. Positive sense viral RNA, indicating occurrence of 
virus replication, was first identified at 8 hpi deep in the lung in type I pneumocytes, 
bronchiolar respiratory epithelial cells and alveolar macrophages. The presence of 




early in this cell type; however, phagocytosis is a major function of alveolar macrophages 
and if virus replication in epithelial cells actually began sometime between our 4 and 8 
hpi time points, it cannot be ruled out that the presence of positive sense viral RNA in 
macrophages may be due to phagocytosis of virus infected epithelial cells prior to 8 hpi.11  
In the lung and nasal cavity, identification of virus infection and replication 
occurred first in epithelial cells that lined air spaces, suggesting that these cells were 
directly infected after inhalational exposure. At subsequent time points, spread from these 
epithelial cell types to adjacent underlying cells, including bronchiolar smooth muscle 
cells, arterial smooth muscle cells in the lung and submucosal gland acinar epithelial cells 
in the nasal cavity, was identified. Viral infection of the vascular endothelium was not 
observed in any tissue at any time point; however, if time points subsequent to 48 hpi 
were analyzed it is likely that Nipah virus would have spread from the arterial smooth 
muscle cells to the overlying vascular endothelial cells in the lung, potentially followed 
by virus dissemination to vessels in other organs and subsequent spread to adjacent 
permissive parenchymal cells. After infection of the lung and nasal cavity, epithelial cells 
lining the trachea and larynx were targeted by Nipah virus at 16 hpi. Based on the lack of 
vascular involvement at this time point, the laryngeal and tracheal epithelial cells were 
likely infected by virus particles disseminating through the airways during respiration.  
 Interestingly, our results showed that in the early phase of infection the spread of 
Nipah virus from epithelial cells that lined airways in the lung and nasal cavity to 
underlying cells appeared to be faster in hamsters inoculated with NiV-M than with NiV-
B, suggesting that development of severe disease may occur faster for NiV-M. However, 




contradictory as to whether disease progression in the respiratory system was faster for 
NiV-M or for NiV-B.2,9 Additionally, end-stage lesions in the respiratory tract appeared 
to plateau at the same severity level by 4 days post inoculation in Syrian hamsters 
inoculated with either Nipah virus isolate,2 indicating that differences noted prior to end-
stage disease may not in fact significantly impact the overall clinical disease severity or 
outcome.  
 In addition to the respiratory tract, we also analyzed the central nervous system, 
lymphoid organs and multisystemic vasculature for evidence of virus dissemination to 
non-respiratory tract tissues. Even at 48 hpi, virus infection and replication were not 
detected in peripheral leukocytes or vessels outside of the lung. Low viral loads were 
observed in the brain and spinal cord in a few NiV-B and NiV-M inoculated hamsters at 
24 or 32 hpi, yet infectious virus and virus replication were not noted. Based on our 
results, spread of Nipah virus to the brain likely occurred through movement of virus 
from the nasal cavity olfactory neurons to the brain by way of the olfactory nerve, rather 
than via a hematogenous route. However, since viral loads in the brain were low, we were 
unable to detect, or track movement of, viral antigen into the brain by IHC. Spread of 
virus from the brain to the thoracolumbar spinal cord may have occurred through the 
cerebrospinal fluid; Nipah virus has been detected in the cerebrospinal fluid of infected 
humans.6 In the lymphoid organs, infectious virus was detected at 48 hpi in the cervical 
lymph nodes of NiV-M inoculated hamsters, but was not present in NiV-B inoculated 
hamsters. Lymphatics from the head and neck drain into the cervical lymph nodes, as 
such, virus could be transported from the nasal cavity to the cervical lymph nodes 




a single NiV-M inoculated hamster and was not identified in any NiV-B inoculated 
hamsters. Spread of Nipah virus to the spleen may have occurred by a hematogenous 
route. Although viremia was not detected at 48 hpi, it is possible that the overall viral 
load in the blood was below the level of detection; however, since the spleen functions to 
remove pathogens from the blood as blood is filtered through the spleen,1,18,25 Nipah virus 
may have accumulated to high enough levels in the spleen that virus could be detected. 
Overall, these results suggest that Nipah virus uses airways to initially 
disseminate throughout the respiratory tract during the early phase of infection. This may 
be followed by dissemination of virus from the nasal cavity to the nervous system by 
neural route, potentially as early as 24 hpi, and dissemination of virus to lymph nodes via 
lymphatic drainage of the nasal cavity. Dissemination of virus, resulting in virally 
infected endothelial cells and smooth muscle cells in blood vessels in multiple organs 
does not appear to occur during the first 48 hpi, yet results suggest that this will occur at a 
later time point. Since Nipah virus can cause encephalitis that results in severe neurologic 
disease in humans and brain stem damage that often causes death, it is important to 
prevent virus dissemination to the brain.10,13 Our data suggest that rapid administration of 
antivirals into the respiratory tract would be the most effective strategy for preventing 
early virus dissemination to the central nervous system, thus potentially lessening disease 
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Table 3.1 Localization of Positive Sense Nipah Virus RNA by In Situ Hybridization in 
the Lungs of Syrian Hamsters Inoculated with a Malaysia Isolate of Nipah Virus 
 
Cell Type Time Post Inoculation (hours) 
 4  8  16  
Type I 
Pneumocytes 
- - - - ++ - ++ - +++ - +++ - 
Alveolar 
Macrophages 
- - - - ++ - ++ - +++ - +++ - 
Bronchiolar 
Respiratory Epi. 
- - - - +++ - +++ - +++ - +++ - 
Bronchiolar 
Smooth Muscle 
- - - - - - - - - - - - 
Bronchial 
Respiratory Epi. 
- - - - - - - - ++ - +++ - 
Arterial Smooth 
Muscle 




Each column represents a single hamster. The columns representing individual hamsters 
in this table correspond to the columns in Tables 3.2, 3.3 and 3.4.   
 
The presence of positive sense Nipah virus RNA was scored in cell types in the lung. 
Scoring protocol: - = negative; + = focal in situ hybridization (ISH) signal; ++ = 
multifocal mild ISH signal; +++ = multifocal moderate ISH signal; ++++ =   multifocal 








Table 3.2 Localization of Positive Sense Nipah Virus RNA by In Situ Hybridization in 
the Nasal Cavity of Syrian Hamsters Inoculated with a Malaysia Isolate of Nipah Virus 
 
Cell Type Time Post Inoculation (hours) 
 4  8  16  
Respiratory 
Epithelium 
NE - - - - - - - - - - ++ 
Olfactory 
Epithelium 
NE NE - - - - - - - - - ++ 
Submucosal Gland 
Epithelium  
NE NE - - - - - - - - - - 
 
NE, not examined. 
 
Each column represents a single hamster. The columns representing individual hamsters 
in this table correspond to the columns in Tables 3.1, 3.3 and 3.4.  
 
The presence of positive sense Nipah virus RNA was scored in cell types in the nasal 
cavity. Scoring protocol: - = negative; + = focal in situ hybridization (ISH) signal; ++ = 
multifocal mild ISH signal; +++ = multifocal moderate ISH signal; ++++ =   multifocal 




Table 3.3 Localization of Nipah Virus Antigen by Immunohistochemistry in the Lungs of Syrian Hamsters Inoculated with a 
Malaysia Isolate of Nipah Virus 
 
Cell Type Time Post Inoculation (hours) 
 4  8  16  24  32  48  
Type I 
Pneumocytes 
- - - - ++ - ++ - ++ - +++ - - ++ - - - +++ - +++ ++++ - ++ - 
Alveolar 
Macrophages 
- - - - ++ - ++ - ++ - +++ - - ++ - - + +++ - +++ ++++ - ++ - 
Bronchiolar 
Respiratory Epi. 
- - - - + - +++ - ++ - +++ - - +++ - - ++ +++ - +++ +++ - ++ - 
Bronchiolar 
Smooth Muscle 
- - - - - - - - - - + - - - - - - - - - ++ - - - 
Bronchial 
Respiratory Epi. 
- - - - - - - - ++ - ++ - - +++ - - ++ ++ - +++ +++ - +++ - 
Arterial Smooth 
Muscle 




Each column represents a single hamster. The columns representing individual hamsters in this table correspond to the columns in 
Tables 3.1, 3.2 and 3.4.  
 
The presence of Nipah virus antigen was scored in cell types in the lung. Scoring protocol: - = negative; + = focal immunopositivity; 






Table 3.4 Localization of Nipah Virus Antigen by Immunohistochemistry in the Nasal Cavity of Syrian Hamsters Inoculated with a 
Malaysia Isolate of Nipah Virus 
 
Cell Type Time Post Inoculation (hours) 
 4 8 16 24 32 48 
Respiratory 
Epithelium 
- - - - - - - - + - - + + - NE ++ ++ + + - ++ ++ ++ + 
Olfactory 
Epithelium 
- - - - - - - - - - - ++ + - NE ++ ++ ++ - - +++ - ++++ + 
Submucosal 
Gland Epi. 
- - - - - - - - - - - - - - NE ++ ++ - - - ++ - +++ - 
 
NE, not examined; Epi, Epithelium. 
 
Each column represents a single hamster. The columns representing individual hamsters in this table correspond to the columns in 
Tables 3.1, 3.2 and 3.3. 
 
The presence of Nipah virus antigen was scored in cell types in the nasal cavity. Scoring protocol: - = negative; + = focal 
immunopositivity; ++ = multifocal mild immunopositivity; +++ = multifocal moderate immunopositivity; ++++ =   multifocal marked 





Table 3.5 Localization of Positive Sense Nipah Virus RNA by In Situ Hybridization in 
the Lungs of Syrian Hamsters Inoculated with a Bangladesh Isolate of Nipah Virus 
 
Cell Type Time Post Inoculation (hours) 
 4 8 16 
Type I 
Pneumocytes 
- - - - ++ ++ ++ ++ +++ +++ ++ - 
Alveolar 
Macrophages 
- - - - ++ ++ ++ ++ +++ +++ ++ - 
Bronchiolar 
Respiratory Epi. 
- - - - + ++ - - +++ +++ +++ - 
Bronchiolar 
Smooth Muscle 
- - - - - - - - - - - - 
Bronchial 
Respiratory Epi. 
- - - - ++ - - - - ++ ++ - 
Arterial Smooth 
Muscle 




Each column represents a single hamster. The columns representing individual hamsters 
in this table correspond to the columns in Tables 3.6, 3.7 and 3.8. 
 
The presence of positive sense Nipah virus RNA was scored in cell types in the lung. 
Scoring protocol: - = negative; + = focal in situ hybridization (ISH) signal; ++ = 
multifocal mild ISH signal; +++ = multifocal moderate ISH signal; ++++ =   multifocal 




Table 3.6 Localization of Positive Sense Nipah Virus RNA by In Situ Hybridization in 
the Nasal Cavity of Syrian Hamsters Inoculated with a Bangladesh Isolate of Nipah Virus 
 
Cell Type Time Post Inoculation (hours) 
 4 8 16 
Respiratory 
Epithelium 
- - - - - - - - + - + + 
Olfactory 
Epithelium 
- - - - - - - - ++ ++ - - 
Submucosal Gland 
Epithelium 
- - - - - - - - - - - - 
 
Each column represents a single hamster. The columns representing individual hamsters 
in this table correspond to the columns in Tables 3.5, 3.7 and 3.8. 
 
The presence of positive sense Nipah virus RNA was scored in cell types in the nasal 
cavity. Scoring protocol: - = negative; + = focal in situ hybridization (ISH) signal; ++ = 
multifocal mild ISH signal; +++ = multifocal moderate ISH signal; ++++ =   multifocal 




Table 3.7 Localization of Nipah Virus Antigen by Immunohistochemistry in the Lungs of Syrian Hamsters Inoculated with a 
Bangladesh Isolate of Nipah Virus 
 
Cell Type Time Post Inoculation (hours) 
 4 8 16 24 32 48 
Type I 
Pneumocytes 
- - - - ++ - ++ ++ +++ +++ ++ - - - ++ ++ ++ +++ - +++ + - ++ + 
Alveolar 
Macrophages 
- - - - ++ - ++ ++ +++ +++ ++ - - - ++ ++ ++ +++ - +++ - - + + 
Bronchiolar 
Respiratory Epi. 
- - - - + - - + ++ ++ + - - - - + + +++ - +++ + - - - 
Bronchiolar 
Smooth Muscle 
- - - - - - - - - - - - - - - - - - - - - - - - 
Bronchial 
Respiratory Epi. 
- - - - - - - + - - - - - - - - - + - - - - - ++ 
Arterial Smooth 
Muscle 




Each column represents a single hamster. The columns representing individual hamsters in this table correspond to the columns in 
Tables 3.5, 3.6 and 3.8. 
 
The presence of Nipah virus antigen was scored in cell types in the lung. Scoring protocol: - = negative; + = focal immunopositivity; 






Table 3.8 Localization of Nipah Virus Antigen by Immunohistochemistry in the Nasal Cavity of Syrian Hamsters Inoculated with 
a Bangladesh Isolate of Nipah Virus 
 
Cell Type Time Post Inoculation (hours) 
 4 8 16 24 32 48 
Respiratory 
Epithelium 
- - - - - - - - ++ - + - - ++ + - ++ NE + - ++ - ++ + 
Olfactory 
Epithelium 
- - - - - - - - ++ + - - - - - - ++ NE + - - - +++ - 
Submucosal 
Gland Epi. 
- - - - - - - - - - - - - - - - - NE - - - - +++ - 
 
NE, not examined; Epi, Epithelium. 
 
Each column represents a single hamster. The columns representing individual hamsters in this table correspond to the columns in 
Tables 3.5, 3.6 and 3.7. 
 
The presence of Nipah virus antigen was scored in cell types in the nasal cavity. Scoring protocol: - = negative; + = focal 
immunopositivity; ++ = multifocal mild immunopositivity; +++ = multifocal moderate immunopositivity; ++++ =   multifocal 






Figure 3.1 A-H. qRT-PCR was used to detect viral RNA in the lung (A), nasal turbinates 
(B), trachea (C), larynx (D), cervical lymph node (E), spleen (F), brain (G) and spinal 
cord (H) at 4, 8, 16, 24, 32 and 48 hpi in Syrian hamsters intranasally inoculated with 
NiV-M. Viral loads in the tissues were determined as TCID50 equivalents. In each run, 
standard dilutions of RNA extracted from a titered virus stock were run in parallel, to 
calculate TCID50 equivalents. Each blue dot indicates a single hamster. Each horizontal 





Figure 3.2 A-F. Virus titration was used to detect infectious virus in the lung (A), nasal 
turbinates (B), trachea (C), larynx (D), cervical lymph node (E) and spleen (F) at 8, 16, 
24, 32 and 48 hpi in Syrian hamsters intranasally inoculated with NiV-M. Virus titers in 
the tissues were determined by titration on Vero C1008 cells. Three days after inoculation 
with tissue homogenates from NiV-M inoculated hamsters, cytopathic effect (CPE) was 
scored and the TCID50 was calculated from 4 replicates by the Spearman-Karber method. 
Each blue dot indicates a single hamster. Each horizontal blue line indicates the mean 





Figure 3.3 A-F. Positive sense viral RNA, indicating the presence of virus replication, 
was detected by ISH in the lung and nasal turbinates at 4, 8 and 16 hpi in Syrian hamsters 
intranasally inoculated with NiV-M. Positive sense viral RNA was not identified at 4 hpi 
in the lung (A), yet was detected in pneumocytes at 8 and 16 hpi (B, C). Positive sense 
viral RNA was not present in the nasal turbinates at 4 or 8 hpi (D, E), but was observed at 





Figure 3.4 A-L. The presence of viral antigen in cells was identified by IHC in the lung 
and nasal turbinates at 4, 8, 16, 24, 32 and 48 hpi in Syrian hamsters intranasally 
inoculated with NiV-M. Nipah virus antigen was not detected at 4 hpi in the lung (A). 
Viral antigen was first detected at 8 hpi in the lung; arrow indicates antigen in 
pneumocytes (B). Increasing amounts of viral antigen were detected in pneumocytes at 
subsequent time points in the lung (C-F). Viral antigen was also detected in bronchiolar 
respiratory epithelium, bronchiolar smooth muscle (black arrow) and arterial smooth 
muscle (inset; red arrow) (F). Viral antigen was not detected in the nasal turbinates at 4 
or 8 hpi (G, H). Viral antigen was first observed in the nasal turbinates at 16 hpi, as 
shown here in the respiratory epithelium (I). Increasing amounts of viral antigen were 
detected in olfactory and respiratory epithelium (J-L). The spread of viral antigen to the 




Figure 3.5 A-D. Detection of positive sense viral RNA, by ISH, and viral antigen, by 
IHC, in the trachea and larynx of Syrian hamsters intranasally inoculated with NiV-M. 
Positive sense viral RNA (A) and viral antigen (B) were identified in respiratory 
epithelial cells in the trachea. Positive sense viral RNA was not identified in the larynx in 






Figure 3.6 A-H.  qRT-PCR was used to detect viral RNA in the lung (A), nasal 
turbinates (B), trachea (C), larynx (D), cervical lymph node (E), spleen (F), brain (G) 
and spinal cord (H) at 4, 8, 16, 24, 32 and 48 hpi in Syrian hamsters intranasally 
inoculated with NiV-B. Viral loads in the tissues were determined as TCID50 equivalents. 
In each run, standard dilutions of RNA extracted from a titered virus stock were run in 
parallel, to calculate TCID50 equivalents. Each blue dot indicates a single hamster. Each 





Figure 3.7 A-D. Virus titration was used to detect infectious virus in the lung (A), nasal 
turbinates (B), trachea (C) and larynx (D) at 8, 16, 24, 32 and 48 hpi in Syrian hamsters 
intranasally inoculated with NiV-B. Virus titers in the samples were determined by 
titration on Vero C1008 cells. Five days after inoculation with tissue homogenates from 
NiV-B inoculated hamsters, cytopathic effect (CPE) was scored and the TCID50 was 
calculated from 4 replicates by the Spearman-Karber method. Each blue dot indicates a 





Figure 3.8 A-F. Positive sense viral RNA, indicating the presence of virus replication, 
was detected by ISH in the lung and nasal turbinates at 4, 8 and 16 hpi in Syrian hamsters 
intranasally inoculated with NiV-B. Positive sense viral RNA was not identified at 4 hpi 
in the lung (A), yet was detected in pneumocytes at 8 hpi (arrow) and 16 hpi (B, C). 
Positive sense viral RNA was not present in the nasal turbinates at 4 or 8 hpi (D, E), yet 
was observed at 16 hpi in the nasal turbinates, as shown here in the olfactory epithelium 





Figure 3.9 A-L. The presence of viral antigen in cells was identified by IHC in the lung 
and nasal turbinates at 4, 8, 16, 24, 32 and 48 hpi in Syrian hamsters intranasally 
inoculated with NiV-B. Nipah virus antigen was not detected at 4 hpi in the lung (A). 
Viral antigen was first detected at 8 hpi in the lung; arrow indicates antigen in 
pneumocytes (B). Increasing amounts of viral antigen were detected in pneumocytes at 
subsequent time points in the lung (C-F). Viral antigen was also detected in bronchiolar 
respiratory epithelium (arrow) (E) and bronchial respiratory epithelium (F). Inset shows 
viral antigen in pneumocytes (arrow) (F). Viral antigen was not detected in the nasal 
turbinates at 4 or 8 hpi (G, H). Viral antigen was first observed in the nasal turbinates at 
16 hpi, as shown here in the olfactory epithelium (I). Increasing amounts of viral antigen 
were detected in olfactory and respiratory epithelium (J-L). The spread of viral antigen to 





Figure 3.10 A-F. Detection of positive sense viral RNA, by ISH, and viral antigen, by 
IHC, in the trachea and larynx of Syrian hamsters intranasally inoculated with NiV-B. 
Positive sense viral RNA was not detected in the trachea of any hamster (A); however, 
viral antigen was observed in epithelial cells lining the trachea (B). Positive sense viral 
RNA was identified in epithelial cells lining the larynx (C), although viral antigen was 
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 Middle East respiratory syndrome coronavirus (MERS-CoV) was initially isolated 
from a Saudi Arabian man with fatal pneumonia. Since the original case in 2012, MERS-
CoV infections have been reported in more than 1100 humans and the case fatality rate is 
currently 38%. This lineage C Betacoronavirus causes a wide range of disease severity, 
ranging from asymptomatic to progressive, fatal pneumonia that may be accompanied by 
renal or multiorgan failure. Although the clinical presentation of human MERS-CoV 
infection has been documented, there are many facets of this emerging disease that are 
still unknown and could be studied using animal models. Several animal models of 
MERS-CoV have been developed, including New Zealand white rabbits, transduced or 
transgenic mice that express human dipeptidyl peptidase 4, rhesus macaques and 
common marmosets. This review provides an overview of the current state of knowledge 
on MERS-CoV infection, the probable origin of this virus and the available animal 
models. Evaluation of the benefits and limitations of these models will aid in appropriate 
model selection for studying viral pathogenesis and transmission as well as for testing 





Middle East respiratory syndrome coronavirus (MERS-CoV) was first isolated 
from a man in Saudi Arabia in 2012 and MERS-CoV infections have now been reported 
in more than 20 countries.68,72 Originally called human coronavirus-EMC/2012, the virus 
was renamed MERS-CoV by the International Committee on Taxonomy of Viruses.19,63 
MERS-CoV is an enveloped, non-segmented, single-stranded, positive-sense RNA virus 
with a genome of 30,119 nucleotides.63 In humans, MERS-CoV is one of six 
coronaviruses that cause respiratory disease; however, it is currently the only known 
pathogenic human lineage C Betacoronavirus.30,64 MERS-CoV infections in humans 
range from asymptomatic to progressive fatal pneumonia with occasional renal or 
multiorgan failure.41,49 To date, published autopsy data from fatal human cases are not 
available, the exact route of viral transmission to, and among, humans is unknown and 
MERS-CoV-specific countermeasures of disease have yet to be approved. Thus, 
development of animal models to study the pathology and pathogenesis of this virus, 
routes of viral transmission and the efficacy of treatments and vaccines is critical. Here, 
we review the current state of knowledge on MERS-CoV infection in humans and 
potential animal reservoirs for the virus and provide an overview and analysis of animal 
models of MERS-CoV infection. 
 
4.3 Human MERS-CoV Infections 
 MERS-CoV was originally reported as a cause of pneumonia in 2012.72 Since the 
initial case, a wide spectrum of disease from asymptomatic to severe, fatal pneumonia 




identified; with the vast majority occurring in the Arabian Peninsula.67 Initially, MERS-
CoV predominantly affected middle-aged males; however, as cases continue to be 
reported, the gap between males and females has narrowed and all age groups ranging 
from children to the elderly have been affected.4,8,9,14,49,52  
The median incubation period from infection to development of disease is 
approximately 5 days.9 Individuals typically present with respiratory symptoms including 
coughing and shortness of breath, often accompanied by nonspecific signs of disease 
such as fatigue, myalgia, arthralgia, fever, headaches, vomiting or diarrhea.11,27,41,50,62 
Lower respiratory tract disease is most often reported; however, some individuals present 
with upper respiratory tract symptoms including a sore throat or rhinorrhea.18,49 In 
patients that develop pneumonia, the disease can rapidly progress to acute respiratory 
distress syndrome sometimes associated with acute renal failure, multiorgan failure and 
death.13,55 The case fatality rate is currently 38%. MERS-CoV infection has also rarely 
been associated with secondary complications such as disseminated intravascular 
coagulation, hyperkalemia or stillbirth.3,51 Severe disease is most common in individuals 
with comorbidities such as hypertension, diabetes mellitus, renal or cardiovascular 
disease, obesity, smoking or immunosuppression.9,27,41,49,69 Asymptomatic or mild 
MERS-CoV infections mainly occur in previously healthy, immunocompetent 
individuals; these cases are being more frequently reported due to increased 
surveillance.14,22,61 Ancillary tests have detected multiple abnormalities in complete blood 
counts, biochemistry panels and radiographs in MERS-CoV infected patients. 
Lymphopenia, neutrophilia, thrombocytopenia and increased levels of c-reactive protein 




lactate dehydrogenase, creatinine and blood urea nitrogen have been identified in some 
individuals, suggesting the development of hepatic and renal disease.11,27,50,72 Pulmonary 
interstitial infiltrates have been documented in radiographs from individuals with 
pneumonia.9,72 MERS-CoV infections are commonly diagnosed by detecting viral RNA 
from several specimen types using real-time PCR.54 Samples obtained from the lower 
respiratory tract, such as bronchoalveolar lavage samples or sputum, are considered the 
most reliable for testing purposes since the highest viral loads have typically been found 
in this location.18,27 However, MERS-CoV has also been detected in nasal or 
oropharyngeal swabs, urine, feces, serum and blood.23,27,34,44  
Humans acquire MERS-CoV through zoonotic transmission and bats and 
dromedary camels are thought to serve as a source of infection.28,40,48 Additionally, 
reports of nosocomial transmission and limited human-to-human transmission in family 
clusters have been documented, with MERS-CoV potentially spreading through 
respiratory droplets, direct contact or fomites.9,27,34,38,39,43,44,49,50,57,61  
 
4.4 The Origin of MERS-CoV 
 Evidence suggests that bats may harbor the ancestor of MERS-CoV, and 
potentially, MERS-CoV itself. Several reports have described a genetic link between 
MERS-CoV and other coronaviruses detected in bats. The lineage C betacoronaviruses, 
Pipistrellus bat coronavirus HKU5 and Tylonycteris bat coronavirus HKU4 are 
genetically related to MERS-CoV and likely emerged from a distant common ancestor 
centuries ago.36 Lineage C betacoronaviruses identified in European and African 




phylogenetically related to MERS-CoV.7 Additionally, in Bisha, Saudi Arabia a few 
months after the first human case of MERS-CoV infection was documented, a short 
coronavirus sequence fragment consisting of 190 nucleotides, which represented the viral 
RNA-dependent RNA polymerase, was isolated from bat feces and shown to share 100% 
sequence identity with the original MERS-CoV isolate from the same geographic 
region.42  
Although MERS-CoV may have originated in insectivorous bats, humans do not 
commonly interact with these species, thus limiting the opportunities for viral 
transmission. Conversely, direct contact between humans and dromedary camels occurs 
on a regular basis in regions with high numbers of reported human MERS-CoV cases and 
dromedary camels have been implicated as a source for human MERS-CoV infections. 
Neutralizing antibodies against MERS-CoV, or a closely related virus, have been 
detected in dromedary camel serum samples collected from several Middle Eastern and 
African countries; seropositivity dated back to 1983.6,15,32,33,40,45,46,53,60 Moreover, MERS-
CoV RNA has been identified in nasal and conjunctival swabs, milk, and rarely rectal 
swabs from dromedary camels.5,12,15,28,40,48,59,71 Although MERS-CoV seropositivity is 
more common in adult camels; MERS-CoV RNA is most often detected in nasal swabs 
from juvenile camels suggesting that active infections typically occur in younger 
camels.5,45 MERS-CoV infections in camels appear to be acute and transient; most 
infected camels are asymptomatic, however, some camels develop rhinorrhea and an 
increase in body temperature.1,10,15,40 Experimental inoculation of young adult dromedary 
camels with MERS-CoV has been shown to cause mild disease consisting of 




tract in the absence of pneumonia.1 Viral antigen and high levels of infectious virus were 
detected in affected tissues while the nasal turbinate respiratory epithelium was identified 
as the main site of virus replication.1 High amounts of infectious virus were isolated from 
nasal discharge despite development of only mild clinical disease,1 which may result in 
MERS-CoV infections being overlooked, leading to undetected viral transmission among 
camels and between camels and humans.  
Epidemiologic data have suggested a link between MERS-CoV infections in 
camels and humans. Direct contact with camels or drinking of unpasteurized camel milk 
has been reported prior to MERS-CoV infection in some humans.41,55 Genetically similar, 
or identical, viral sequences have been isolated from camels and individuals caring for 
these animals, with serologic data in one case providing evidence for camel-to-human 
transmission.10,28,40 Although the exact mode of transmission between camels and 
humans is unknown, it is speculated that transmission may occur through direct contact, 
ingestion of unpasteurized camel milk, or contact with respiratory droplets or nasal 
secretions, which have been shown to carry high viral loads.1,9,26,41 Despite the high 
prevalence of MERS-CoV in camels, viral transmission from camels to humans appears 
to be limited and multiple countries with seropositive camels have yet to detect MERS-
CoV infections in humans.17,31,46 
 
4.5 MERS-CoV Species Tropism 
 Dipeptidyl peptidase 4 (DPP4, also known as CD26) has been identified as the 
receptor for the MERS-CoV spike protein (S) and is required for viral binding and entry 




epithelial and endothelial cells throughout the body.35 Although DPP4 is evolutionarily 
conserved, differences in the amino acids present in its extracellular domain, which binds 
MERS-CoV S, have been noted among various animal species and humans. Specifically, 
14 amino acids in DPP4 appear to be critical in determining whether the MERS-CoV S 
can bind to DPP4.66 MERS-CoV S cannot bind to DPP4 in species that have significant 
differences in these 14 amino acids, such as ferrets, hamsters and mice, thus these species 
are resistant to infection.37,65 Species with few or no differences in the 14 amino acids can 
be infected by MERS-CoV, including rhesus macaques, common marmosets and 
camels.24,47,65 In addition to analyzing the DPP4 amino acid sequence, evaluation of the 
binding energies between MERS-CoV and DPP4 has proven useful in assessing whether 
MERS-CoV S can bind to DPP4 from different species. A low binding energy between 
DPP4 and MERS-CoV S has been associated with susceptibility to MERS-CoV infection; 
whereas high binding energies are reported between MERS-CoV S and DPP4 from 
nonpermissive species.24,65 Determination of binding energies can guide the selection of 
animal species when developing animal models of MERS-CoV infection. 
 
4.6 Animal Models of MERS-CoV Infection 
 As indicated above, several laboratory animal species that are often used to model 
viral diseases are not susceptible to MERS-CoV infection due to differences in critical 
amino acids in the S-binding domain of DPP4. Multiple strains of wildtype and knockout 
mice, Syrian hamsters and ferrets have all been shown to be resistant to MERS-CoV 
infection.16,20,58 Despite a lack of conventional small animal models, researchers have 




rabbits, human DPP4 transduced or transgenic mice, rhesus macaques and common 
marmosets (summarized in Tables 4.1 and 4.2). Below, each of these animal models of 
MERS-CoV are discussed in detail. 
 
4.6.1 Rabbits 
 New Zealand white rabbits have been described as an animal model of 
asymptomatic MERS-CoV infection (Table 4.1).29 Rabbits were inoculated with a total 
dose of 5 x 106 TCID50 of MERS-CoV through intratracheal and intranasal routes and 
then euthanized 3, 4 or 21 days post inoculation (dpi). Clinical signs, including weight 
loss, were not observed in infected rabbits. Gross lesions were not reported in any organ 
examined. Microscopically, lesions were detected in the upper and lower respiratory tract 
at 3 and 4 dpi. In the nasal cavity, there was a mild to moderate infiltration of heterophils 
that in some cases was accompanied by epithelial necrosis and regeneration (Figure 4.1 
A). The lungs exhibited mild heterophilic infiltration in alveolar septa and lumina, 
predominantly around terminal bronchioles (Figure 4.1 B). Type II pneumocyte 
hypertrophy and hyperplasia of bronchus-associated lymphoid tissue were also observed.  
Virus was detected in tissues in the upper and lower respiratory tract by 
quantitative real-time PCR (qRT-PCR), in situ hybridization (ISH) and 
immunohistochemistry (IHC) (Table 4.2). Microscopically, viral antigen was observed in 
respiratory and olfactory epithelium in the nasal cavity, where it colocalized with lesions, 
and was present in the lungs in type I and type II pneumocytes and epithelium lining 
bronchi and bronchioles. Additionally, virus titration revealed the presence of infectious 





 Although wildtype mice are not susceptible to MERS-CoV infection,16 two mouse 
models of MERS-CoV infection have been developed by expressing human DPP4 in 
these animals (summarized in Tables 4.1 and 4.2). In the first model, an adenoviral vector 
was used to induce transient expression of human DPP4 in the lungs of BALB/c mice, 
C57BL/6 mice and multiple knockout mouse strains.73 Human DPP4 was only expressed 
by epithelial cells lining the airways and alveoli. After human DPP4 transduction, the 
mice were inoculated intranasally with 1 x 105 plaque forming units of MERS-CoV. 
Clinical signs in the human DPP4 transduced wildtype mice were minimal and 
characterized by lack of weight gain in young mice and mild weight loss in older mice. 
Mice exhibited mild pulmonary gross lesions which corresponded to peribronchial and 
perivascular inflammation that developed into interstitial pneumonia (Figure 4.1 C, D). 
IHC showed MERS-CoV antigen was colocalized with human DPP4 expression in the 
lungs. Virus replication was detected in the lungs by 2 dpi; however, viral infection was 
transient. Clearance of MERS-CoV from the lungs was faster in younger mice. 
Transduced knockout mice, which had impaired immune systems such as a lack of type-I 
IFN signaling (IFNAR-/-), typically exhibited earlier, more severe clinical signs and 
gross and microscopic lesions than infected transduced wildtype mice (Figure 4.1 E, F). 
In all mouse strains, gross and microscopic lesions and virus replication were not present 
in organs outside of the respiratory tract, which fits with the lack of detectable human 
DPP4 in these tissues. 
For the second mouse model, transgenic mice were developed that globally 




neurons in the brain and endothelial cells in multiple tissues.2 Five to seven week old 
transgenic mice expressing human DPP4 were intranasally inoculated with 106 TCID50 of 
MERS-CoV. The transgenic mice exhibited severe, progressive respiratory disease. 
Infected mice lost weight, were lethargic and exhibited rapid, shallow breathing. By 6 dpi, 
the infection was fatal in 100% of the mice. Gross lesions were only noted in the lungs; 
microscopic lesions were observed in the lungs and brain (Figure 4.2 A-D). Pulmonary 
gross lesions were characterized as red areas of consolidation that were more extensive at 
4 dpi than 2 dpi. Histologically, mice had bronchointerstitial pneumonia with 
perivasculitis that was more severe at 4 dpi than 2 dpi. A single mouse exhibited 
perivascular cuffing in the brain.  
In the transgenic mice, high levels of infectious virus (approximately 107 
TCID50/g) were detected in the lung at 2 dpi, while lower levels (approximately 104 
TCID50/g) were detected at 4 dpi. Infectious virus was only detected at 4 dpi in the brain; 
the mean viral titer in the brain was 7 x 104 TCID50/g. Viral RNA was detected not only 
in the lung and brain, but also in visceral organs such as the heart and spleen, suggesting 
widespread viral dissemination had occurred. Infectious virus and viral RNA were not 
present in the kidneys. Through IHC, viral antigen was detected in type I and type II 
pneumocytes in the lungs and microglia, astrocytes and neurons in the brain. Based on 
the results, it appeared that the respiratory system was the earliest target for MERS-CoV. 
 
4.6.3 Rhesus Macaques 
 Koch’s postulates for MERS-CoV were fulfilled in rhesus macaques, which were 




acute, transient, mild to moderate respiratory disease after either intratracheal inoculation 
with 6.5 x 107 TCID50 of MERS-CoV70 or inoculation with a total dose of 7 x 106 TCID50 
of MERS-CoV via the ocular, oral, intratracheal and intranasal routes (Table 4.1).21,25,47 
Infected macaques exhibited respiratory clinical signs such as tachypnea, deep abdominal 
breathing and coughing.21,47 Nonspecific signs of illness such as anorexia, hunched 
posture and fever were also reported.21,47,70 Clinical signs were observed by 1 dpi and 
resolved as early as 4 dpi.21 Correspondingly, serial complete blood counts showed 
development of a lymphopenia and leukocytosis accompanied by neutrophilia 1 dpi, 
which resolved by 3 dpi.21 
Rhesus macaques that were euthanized at either 3 or 6 dpi developed gross lesions 
only in the lungs; lesions consisted of firm, edematous, bright to dark red discolored foci 
(Figure 4.2 E).47,70 Histologic pulmonary lesions were described as either an interstitial 
pneumonia70 or a bronchointerstitial pneumonia which centered on terminal bronchioles, 
with development of hyaline membranes and type II pneumocyte hyperplasia (Figure 4.2 
F).21,25 In pulmonary lesions and serum, transient upregulation of proinflammatory 
mediators, including interleukin-6 and chemokine (C-X-C motif) ligand 1, were 
identified.21 Additionally, MERS-CoV specific neutralizing antibodies were detected in 
serum samples as early as 7 dpi.70 
Infectious virus was isolated from the lungs47,70 (peak titer was approximately 105 
TCID50/gram) and MERS-CoV RNA was detected in several upper and lower respiratory 
tract tissues, including the lungs, nasal mucosa, trachea and bronchi (Table 4.2).21 
MERS-CoV RNA was also identified in nasal swabs, bronchoalveolar lavage samples 




viral shedding from the upper respiratory tract, lesions and virus replication were only 
observed in lower respiratory tract tissues with virus replication occurring in type I and 
type II pneumocytes.21 Sites of virus replication and the location of viral antigen, as 
determined by IHC, correlated with the reported sites of cellular expression of DPP4 in 
the lungs of rhesus macaques.21,65 Viral antigen in the lung was exclusively present in 
areas of pneumonia.21,70 Viral RNA was not present in blood or any visceral organs, 
including the kidney.21,70 
 
4.6.4 Common Marmosets 
 MERS-CoV caused severe, potentially lethal respiratory disease in common 
marmosets inoculated with a total dose of 5.2 x 106 TCID50 of MERS-CoV administered 
through a combination of ocular, oral, intratracheal and intranasal routes (Table 4.1).24 
Infected marmosets developed moderate to severe clinical signs which necessitated early 
euthanasia of two out of nine marmosets. Clinical signs included tachypnea, labored or 
shallow breathing, cyanosis, hemorrhagic oral discharge, anorexia and hunched posture. 
Clinical signs were first noted 1 dpi, peaked at 4-6 dpi and resolved by 13 dpi. 
Correspondingly, radiographs showed pulmonary interstitial infiltration as early as 1 dpi; 
infiltrates were no longer evident by 13 dpi.  
Gross lesions were present only in the lungs of marmosets necropsied 3, 4 or 6 dpi. 
Affected lung lobes were dark red, edematous and failed to collapse (Figure 4.2 G). 
Microscopically, the pulmonary gross lesions corresponded to foci of bronchointerstitial 
pneumonia that centered on terminal bronchioles and extended into adjacent parenchyma 




the lesions diffusely affected the examined tissue. The pneumonia was characterized by 
hyaline membranes, alveolar edema, hemorrhage, fibrin and type II pneumocyte 
hyperplasia often with severe airway lesions affecting bronchi and bronchioles. In foci of 
pneumonia, there was upregulation of RNA for molecules involved in proinflammatory 
and antiviral pathways and fibrogenesis. 
IHC detected abundant MERS-CoV antigen in type I and type II pneumocytes and 
macrophages within foci of pneumonia (Table 4.2). ISH indicated that type I 
pneumocytes and alveolar macrophages were the main sites of virus replication and IHC 
showed that these cell types expressed DPP4. High levels of viral RNA were detected in 
the lung while lower levels were present in upper respiratory tract tissues and nasal and 
oropharyngeal swabs. Infectious virus was isolated from both upper and lower respiratory 
tract tissues; the peak pulmonary titer was approximately 107 TCID50/g. MERS-CoV 
RNA was also detected in several visceral organs, including the kidney, and in blood 
from marmosets necropsied 6 dpi or prior. Identification of viremia and viral RNA in 
multiple organ systems suggested that MERS-CoV widely disseminated throughout the 
body of marmosets; however, lesions were only present in the respiratory tract.  
 
4.7 Advantages and Limitations of Animal Models of MERS-CoV Infection 
 Several animal models of MERS-CoV infection have been developed, each of 
which has its own set of benefits and limitations (summarized in Table 4.3). Rabbits, 
human DPP4 transduced and transgenic mice, rhesus macaques and common marmosets 
were all susceptible to MERS-CoV infection, although disease severity was markedly 




their upper respiratory tract and could potentially be used to study MERS-CoV 
transmission; however, they are not suitable for studying clinical disease progression as 
they remained asymptomatic after MERS-CoV inoculation. Overall, this model seems to 
be of limited value. Human DPP4 transduced mice could be used to model mild MERS-
CoV disease, as they exhibited mild, transient clinical disease and pulmonary lesions, 
although respiratory clinical signs were not noted. An increase in clinical disease severity 
with earlier onset of gross and microscopic lesions was achieved by transducing 
immunodeficient knockout mice. These mice could be used to study the impact of 
different aspects of the immune system on MERS-CoV disease. However, the human 
DPP4 transduced mouse model is of limited value for screening antivirals and vaccines 
since disease and human DPP4 expression are transient. Currently, the human DPP4 
transgenic mouse is the only available small animal model of severe, lethal MERS-CoV 
respiratory disease. However, these mice globally express human DPP4 which resulted in 
development of both respiratory and nervous system lesions, which may not be 
representative of human MERS-CoV infection. Nevertheless, this model is ideal for 
screening the efficacy of antivirals and vaccines. 
Two nonhuman primate models of MERS-CoV infection develop both clinical 
respiratory disease and pneumonia. The disease in rhesus macaques was transient and 
similar to mild human cases of MERS-CoV, while common marmosets modeled severe, 
potentially lethal respiratory disease. In comparison to the small animal models, the 
nonhuman primates have respiratory and immune systems that are more similar to 
humans. Additionally, the larger size of the macaques allowed repeated blood sampling, 




humans. Both nonhuman primate models, however, have disadvantages in regards to 
difficulties in handling in biocontainment, costs and animal ethics. Nevertheless, both 
models can satisfy confirmatory efficacy testing requirements for vaccines and antivirals 
under the Food and Drug Administration Animal Efficacy Rule; however, the lower body 
weight and development of more severe disease makes common marmosets better suited 
for antiviral testing.   
Acute renal failure has been reported in some humans with MERS-CoV infections, 
although this has not been observed in any of the available animal models. However, 
when present in humans, acute renal failure appears to develop late in the disease course 
and is thought to occur secondary to shock, or in association with previous renal disease, 
rather than as a result of viral-induced injury. In support of this, common marmosets 
exhibited viremia and viral RNA was detected in their kidneys despite a lack of renal 
disease, suggesting that renal failure is not a direct consequence of MERS-CoV infection.  
 
4.8 Conclusions 
 Taken together, the animal models reviewed here replicated the wide range of 
disease severity observed in MERS-CoV infected humans, which spans from 
asymptomatic to severe, fatal pneumonia. Although each model had important limitations, 
the available animal models can be used to address current gaps in our knowledge of 
MERS-CoV disease. Appropriate selection of the most suitable animal model will allow 
researchers to study the pathogenesis and transmission of MERS-CoV and development 
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Table 4.1 Summary of the inoculation route and dose, clinical disease and gross and microscopic lesions that develop in animal 
models of Middle East respiratory syndrome coronavirus infection.  
 
Animal Species Inoculation Route 
and Dose 




IT, IN  
5 x 106 TCID50 
Asymptomatic Absent Heterophilic rhinitis, pulmonary 









Lack of weight gain or 












106 TCID50  
Severe respiratory 











OC, oral, IT, IN 
7 x 106 TCID50  
 
IT 
6.5 x 107 TCID50 
 



















OC, oral, IT, IN 
5.2 x 106 TCID50 
Severe respiratory 
disease, potentially fatal 




IT, intratracheal; IN, intranasal; OC, ocular; TCID50, 50% tissue culture infectious dose; hDPP4, human dipeptidyl peptidase 4; 









Table 4.2 Summary of the tissues and cell types containing viral RNA, viral antigen or 




MERS-CoV, Middle East respiratory syndrome coronavirus; LN, lymph nodes; N/D, not 
determined; TCID50, 50% tissue culture infectious dose; URT, upper respiratory tract 
tissues. aMERS-CoV RNA was detected by quantitative real-time PCR. bMERS-CoV 






Animal Species MERS-CoV 
RNAa 













Nasal olfactory and respiratory 
epithelium 
Bronchial and bronchiolar 
epithelium 












Visceral organs  
 
Type I and type II pneumocytes 












Type I and type II pneumocytes 
Alveolar macrophages 









Type I pneumocytes 
Alveolar macrophages 
Lung  







Table 4.3 Summary of the advantages and limitations of animal models of Middle East 
respiratory syndrome coronavirus infection. 
 
Animal Species Advantages Limitations 
New Zealand White 
Rabbits 
 
Inexpensive and easy to obtain 
 
No clinical disease 





Mice can be generated rapidly 
Mice of various genetic backgrounds can be 
transduced 
Easy to handle and house 
Reagents and assays are widely available 
 
Clinical disease is transient 
Disease is reliant on transduction 
efficacy 
hDPP4 is expressed transiently and 






Model severe, fatal MERS-CoV infection 
Easy to handle and house 
Reagents and assays are widely available 
Useful for screening antivirals and vaccines 
 




Model mild MERS-CoV infection 
Repeated blood sampling is possible 
Reagents available for immunological analysis 
Respiratory and immune systems similar to 
humans 
Useful for confirming vaccine efficacy testing  
 
Disease is transient 
Expert husbandry required 
Expensive to obtain 
Ethical concerns 
 
Common Marmosets Model severe, potentially fatal MERS-CoV 
infection 
Respiratory and immune systems similar to 
humans 
Useful for confirming antiviral and vaccine 
efficacy testing 
Expert husbandry required 
Expensive to obtain and of limited 
availability 
Ethical concerns 
Few species-specific reagents 
available 
 







Figure 4.1 A. Middle East respiratory syndrome coronavirus (MERS-CoV) infection, 
nasal cavity, New Zealand white rabbit. Mild heterophilic infiltration of the nasal cavity 
respiratory epithelium (arrow). Hematoxylin and eosin (HE). B. MERS-CoV infection, 
lung, New Zealand white rabbit. Rare heterophilic infiltration in the alveolar septa 
(arrow). HE. C-F. MERS-CoV infection, mouse, lung. Images for C-F were taken 7 days 
post inoculation (dpi). C. Pulmonary congestion and inflammation in a C57BL/6 human 
DPP4 (hDPP4) transduced mouse. D. Mild peribronchiolar and perivascular 
inflammation in a C57BL/6 hDPP4 transduced mouse. HE. E. Pulmonary congestion and 
inflammation in an hDPP4 transduced mouse that lacked type-I IFN signaling      
(IFNAR-/-). The pulmonary lesions were more severe than in the C57BL/6 hDPP4 
transduced mice. F. Moderate peribronchiolar and perivascular inflammation in an 







Figure 4.2 A-D. Middle East respiratory syndrome coronavirus (MERS-CoV) infection, 
mouse, lung. Images for A and B were taken 2 days post inoculation (dpi) and C and D 
were taken 4 dpi. A. Pulmonary consolidation in an hDPP4 transgenic mouse. B. 
Bronchointerstitial pneumonia in an hDPP4 transgenic mouse. Hematoxylin and eosin 
(HE). C. Pulmonary consolidation in an hDPP4 transgenic mouse. D. Bronchointerstitial 
pneumonia in an hDPP4 transgenic mouse. HE. E-H. MERS-CoV infection at 3 dpi, 
nonhuman primate, lung. E. Interstitial pneumonia, seen as dark red foci, in a rhesus 
macaque. F. Bronchointerstitial pneumonia with infiltration of neutrophils and 
macrophages in a rhesus macaque. HE. G. Interstitial pneumonia, seen as dark red foci, 
in a common marmoset. H. Bronchointerstitial pneumonia with bronchiolar erosions 
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Middle East respiratory syndrome coronavirus (MERS-CoV) was first identified 
in a human with severe pneumonia in 2012. Since then, infections have been detected in 
more than 1000 individuals with disease severity ranging from asymptomatic to severe, 
fatal pneumonia. To elucidate the pathogenesis of this virus and investigate mechanisms 
underlying disease severity variation in the absence of autopsy data, a rhesus macaque 
and common marmoset model of MERS-CoV disease were analyzed. Rhesus macaques 
developed mild disease and common marmosets exhibited moderate to severe, potentially 
lethal, disease. Both nonhuman primate species exhibited respiratory clinical signs post 
inoculation, which were more severe and of longer duration in the marmosets, and 
developed bronchointerstitial pneumonia. In marmosets, the pneumonia was more 
extensive with development of severe airway lesions. Quantitative analysis showed 
significantly higher levels of pulmonary neutrophil infiltration and higher amounts of 
pulmonary viral antigen in marmosets. Pulmonary expression of the MERS-CoV receptor, 
dipeptidyl peptidase 4, was similar in marmosets and macaques. These results suggest 
that increased virus replication and the immune response to MERS-CoV infection likely 
play a role in pulmonary pathology severity. Together, the rhesus macaque and common 
marmoset models of MERS-CoV span the wide range of disease severity reported in 






 Middle East respiratory syndrome coronavirus (MERS-CoV) was first isolated in 
2012 from a person with fatal acute pneumonia in Saudi Arabia.29 Since the initial case, 
more than 1000 human cases of MERS-CoV infection have been detected, mainly in or 
near the Arabian Peninsula.6,27 Dromedary camels, common in the Arabian Peninsula, are 
thought to serve as a reservoir for MERS-CoV,2 which may in part explain the clustering 
of human MERS-CoV infections in this geographic location. The exact route of 
transmission of MERS-CoV from camels to humans has not been identified, although 
dromedary camels infected with MERS-CoV have been shown to secrete high amounts of 
infectious virus in their nasal discharge1 and viral RNA has been detected in their milk.21 
MERS-CoV disease ranges from asymptomatic to severe, fatal pneumonia with 
acute respiratory distress syndrome occasionally accompanied by renal failure or 
gastrointestinal disease.28 Most patients present with a fever and respiratory symptoms, 
which rapidly progress to pneumonia. The most common respiratory symptoms are 
attributed to lower respiratory tract disease and include dyspnea and coughing.22 Few 
individuals solely develop mild upper respiratory tract symptoms, such as a sore 
throat.5,22 Severe disease, and death, due to MERS-CoV infection is most common in 
individuals affected by comorbidities, including diabetes, renal or cardiac disease and 
hypertension.4 The current case fatality rate is approximately 38%; however, no autopsy 
reports detailing the lesions in fatal infections have been published to date.27 In order to 
elucidate the pathogenesis MERS-CoV infection and investigate mechanisms underlying 
the variation in disease severity, two nonhuman primate models were developed. These 




MERS-CoV inoculation, rhesus macaques developed mild to moderate disease while 
common marmosets exhibited moderate to severe, potentially lethal, disease.7,8  
Clinical description and virology of MERS-CoV infection in the rhesus macaque 
and common marmoset models have been reported.7,8 Here we focus on detailed and 
specific histopathology aspects of the respiratory tract of infected animals to establish the 
mechanism of pathogenicity. To this end, we scored and quantitatively analyzed the 
bronchointerstitial pneumonia in both nonhuman primate species post-MERS-CoV 
inoculation and quantified MERS-CoV antigen in the lungs. Increased numbers of 
neutrophils in the lung and higher amounts of MERS-CoV antigen were observed in 
marmosets. However, marmosets and macaques had similar pulmonary expression of the 
MERS-CoV receptor, dipeptidyl peptidase 4. These results suggest that increased 
pulmonary virus replication and a robust immune response to MERS-CoV infection may 
play a role in pulmonary lesion severity, with higher viral loads and a more pronounced 
acute inflammatory response observed in marmosets. 
 
5.3 Materials and Methods 
 
5.3.1 Ethics and Biosafety Statements 
 All animal experiments were approved by the Rocky Mountain Laboratories 
(RML) Institutional Animal Care and Use Committee and were performed following the 
guidelines of the Association for Assessment and Accreditation of Laboratory Animal 
Care, International (AALAC) by certified staff in an AALAC-approved facility. All 




(IBC) and performed in a high containment facility at RML. Sample inactivation was 
performed according to standard operating procedures (SOP) approved by the IBC for 
removal of specimens from high containment. 
 
5.3.2 Nonhuman Primates 
 Archived tissue blocks from nine rhesus macaques (five males, four females; aged 
4-10 years) inoculated with a total dose of 7 x 106 50% tissue culture infectious dose 
(TCID50) of MERS-CoV and seven common marmosets (seven males; aged 2-6 years) 
inoculated with a total dose of 5.2 x 106 TCID50 of MERS-CoV, as described previously, 
7-9,16 were analyzed histologically. The rhesus macaques (RM1-9) and common 
marmosets (CM1-7) were randomly assigned a number. Necropsies of the animals were 
scheduled for 3 days post inoculation (dpi) (CM1-3, RM1-6) and 6 dpi (CM4-6 and RM 
7-9). The remaining common marmoset (CM7) was not originally scheduled for 
euthanasia, instead it was to be used to study long-term survival; however, due to 
development of severe clinical signs this animal was euthanized 4 dpi. A complete set of 
tissues from each animal was collected at necropsy. 
 
5.3.3 Histopathology and Immunohistochemistry 
 Histopathology and immunohistochemistry (IHC) were performed on rhesus 
macaque and common marmoset tissues. Tissues were fixed according to SOP for a 
minimum of 7 days in 10% neutral-buffered formalin, embedded in paraffin and stained 
with hematoxylin and eosin (H&E). The severity of the bronchointerstitial pneumonia 




of 0 to 4. 0 = no lesions present. 1 = few inflammatory foci present; alveolar septa 
minimally thickened by congestion, neutrophils and macrophages; few neutrophils and 
macrophages infiltrate alveoli. 2 = multiple inflammatory foci present in one or more 
lobes; alveolar septa mildly thickened by congestion, neutrophils and macrophages; 
neutrophils and macrophages mildly infiltrate alveoli. 3 = multiple inflammatory foci 
present within a single lung lobe; alveolar septa moderately thickened by congestion, 
neutrophils and macrophages; neutrophils and macrophages moderately infiltrate alveoli; 
small amounts of fibrin and edema in alveoli. 4 = multifocal to coalescing inflammatory 
foci present within a single lung lobe; alveolar septa markedly thickened by congestion, 
neutrophils and macrophages; large numbers of neutrophils and macrophages, fibrin and 
edema in alveoli. 
IHC with a rabbit polyclonal antiserum against HCoV-EMC/2012 (1:1000, RML, 
Hamilton, MT)12 as a primary antibody was used to detect MERS-CoV antigen. IHC was 
further used to detect neutrophils (polyclonal goat anti-myeloperoxidase, 1:450, R&D 
Systems, Minneapolis, MN), T cells (monoclonal rabbit anti-CD3, pre-diluted, Ventana, 
Tucson, AZ), B cells (polyclonal rabbit anti-CD20, 1:100, Thermo Scientific, Waltham, 
MA), macrophages (polyclonal rabbit anti-Iba1, 1:1000, RML, Hamilton, MT), epithelial 
cells (polyclonal rabbit anti-pan cytokeratin, 1:50, Novus Biologicals, Littleton, CO) and 
dipeptidyl peptidase 4 (polyclonal rabbit anti-CD26, 1:400, Abcam, Cambridge, MA). 
Sections of lung from animals necropsied 3 dpi that were labeled for MERS-CoV antigen 
or inflammatory cell markers were digitized using an Aperio Digital Slide Scanner (Leica, 
Wetzler, Germany) and analyzed using the positive pixel count algorithm in ImageScope 




the percentage of the pulmonary tissue that was positively labeled for MERS-CoV 
antigen or a specific type of inflammatory cell and the percentage of pulmonary tissue 
that did not express the IHC marker of interest, but which was labeled by a background 
stain. Positive pixel count algorithm calculations are based on the amount of a specific 
stain present in a digitized slide and do not include non-stained areas such as spaces filled 
with air. The lung lobe section that was most severely affected by bronchointerstitial 
pneumonia was analyzed in each animal. 
 
5.3.4 Statistical Analysis 
 Statistical analyses were performed using the unpaired student’s t-test. P < 0.05 
was considered statistically significant. All statistics were performed using GraphPad 




5.4.1 Widespread Bronchointerstitial Pneumonia Develops in Common Marmosets 
 Macaques and marmosets developed bronchointerstitial pneumonia 
predominantly centered on terminal bronchioles.7-9,16 In rhesus macaques, the pulmonary 
lesions ranged from mild to severe; however, even in lung lobes with severe lesions, the 
lesions were multifocal and often surrounded by large areas of normal lung tissue (Figure 
5.1 A, C). The bronchointerstitial pneumonia in common marmosets was of moderate to 
marked severity and was multifocal to coalescing, with some lobes diffusely affected 




each lung lobe was scored on a scale of 0-4. The average histologic score for the 
pneumonia was significantly higher (P < 0.05) in the marmosets than the macaques at 3 
dpi, 3.2 versus 1.3 respectively, and at 6 dpi, 3.3 versus 1.1 respectively (Figure 5.1 E, F). 
The more severe bronchointerstitial pneumonia that developed in common marmosets fit 
with the more severe respiratory clinical signs and more extensive pulmonary gross 
pathology that has previously been reported in common marmosets as compared to rhesus 
macaques. 7-9,16 
 
5.4.2 Pulmonary Multinucleated Cells are Predominantly of Macrophage Origin 
 In both nonhuman primate species, and at all time points, the bronchointerstitial 
pneumonia was accompanied by multinucleated cells in alveoli or on the surface of 
alveolar septa. IHC for Iba1 (Figure 5.2 A, B) and pan cytokeratin (Figure 5.2 C, D) on 
sections of lung tissue demonstrated that the multinucleated cells were a mixed 
population of cells. More than 80% of the multinucleated cells expressed Iba1 indicating 
they were of macrophage origin; epithelial syncytia that expressed pan cytokeratin made 
up the remainder of the multinucleated cells.  
 
5.4.3 Airway Lesions are More Severe in Common Marmosets 
 The lesions that developed in bronchi and bronchioles in common marmosets 
necropsied 3, 4 or 6 dpi were more severe than those observed in rhesus macaques. The 
respiratory epithelium that lined bronchi was rarely damaged in macaques; when 
epithelial lesions were present, mild respiratory epithelial degeneration with loss of cilia 




neutrophils with fewer macrophages (Figure 5.3 C). Occlusion of bronchioles by large 
accumulations of fibrin was not observed in macaques at any time point. At all time 
points, affected bronchi and bronchioles in common marmosets were multifocally eroded 
and lined by attenuated respiratory epithelium that lacked cilia (Figure 5.3 B). Airways 
were often infiltrated predominantly by neutrophils and macrophages which were 
occasionally mixed with accumulations of fibrin (Figure 5.3 D).  
 
5.4.4 Higher Amounts of Pulmonary Viral Antigen are Detected in Common 
Marmosets 
  MERS-CoV antigen was detected by IHC in sections of lung from 
marmosets and macaques necropsied 3 dpi (Figure 5.4 A, B). Common marmosets had a 
significantly higher mean percentage of the lung positively labeled for MERS-CoV 
antigen than rhesus macaques, 12.2% versus 3.6%, respectively (P = 0.027) (Figure 5.4 
C). In both species, MERS-CoV antigen was detected predominantly in type I and type II 
pneumocytes and occasionally in macrophages. The results from the quantification of 
pulmonary MERS-CoV antigen fit with previously reported pulmonary viral RNA loads 
detected by qRT-PCR. Retrospective pooling and re-analysis of pulmonary viral RNA 
load data from rhesus macaque7,9  and common marmoset lung tissues8 show that at 3 dpi 
and 6 dpi, common marmosets had pulmonary viral RNA loads up to one thousand times 






5.4.5 Pulmonary Neutrophil Infiltration is Significantly Higher in Common Marmosets 
 IHC was performed on lung from marmosets and macaques necropsied at 3 dpi to 
detect neutrophils, T lymphocytes, B lymphocytes and macrophages. The percentage of 
the pulmonary section that was positively labeled for each type of leukocyte was 
quantified by ImageScope (Figure 5.5 A-L). The mean percentage of the lung infiltrated 
by neutrophils, as detected by myeloperoxidase IHC, was significantly higher (P < 0.001) 
for marmosets (30.5%) than macaques (8.3%). In both species, neutrophils were 
numerous in alveolar spaces, with fewer neutrophils in airways, alveolar septa and blood 
vessels. The mean percentage of the lung infiltrated by T lymphocytes, B lymphocytes or 
macrophages in rhesus macaques as compared to common marmosets was similar (P > 
0.05). In both species, T and B lymphocytes exhibited segmental to circumferential 
cuffing of blood vessels, bronchi and bronchioles and were widely scattered within 
alveolar septa and blood vessels and rarely present in alveolar spaces or airways (Figure 
5.6 A-D). In rhesus macaques, lymphoid follicles were adjacent to bronchi or bronchioles. 
Lymphoid follicles were rarely observed in common marmosets. In both species, 
lymphoid follicles were composed of centrally located B lymphocytes cuffed by T 
lymphocytes with variable numbers of macrophages scattered among the B and T 
lymphocytes. In macaques and marmosets, macrophages were predominantly identified 
within alveolar spaces and septa, while fewer macrophages were found cuffing vascular 
walls and airways or were detected within airways and vascular lumina (Figure 5.6 E, F). 
The mean percentage of the lung infiltrated by macrophages was higher than that for T or 





5.4.6 Dipeptidyl Peptidase 4 is Expressed by Similar Cell Types in the Lungs of Rhesus 
Macaques and Common Marmosets 
 To determine whether the difference in lesion severity between common 
marmosets and rhesus macaques could be explained by a difference in expression of the 
receptor for MERS-CoV, IHC for dipeptidyl peptidase 4 (DPP4) was performed on lung 
(Figure 5.7 A, B). In both rhesus macaques and common marmosets, DPP4 was 
expressed by pneumocytes, airway epithelium, smooth muscle cells, endothelium, and 
macrophages. Similar percentages of each cell type expressed DPP4 in marmosets and 
macaques. In both species, MERS-CoV antigen was detected in several of the cell types 




 Epidemiologic data indicate there is marked variation in clinical disease severity 
in humans infected with MERS-CoV.14,22,28 This manuscript details the differences and 
similarities in pulmonary lesion severity, influx of inflammatory cells into the lungs and 
pulmonary viral antigen and RNA loads in two nonhuman primate models of MERS-CoV 
disease exhibiting mild versus severe disease.  
A mixed population of multinucleated cells were observed in areas of 
bronchointerstitial pneumonia in macaques and marmosets; multinucleated cells were 
predominantly of macrophage origin while the remainder were of epithelial origin. Other 
coronaviruses, including severe acute respiratory syndrome (SARS) coronavirus, which 




multinucleated cells of macrophage origin or epithelial origin.12,24 Viral-induced cell-to-
cell fusion may have caused the formation of the multinucleated cells in the MERS-CoV 
inoculated macaques and marmosets. MERS-CoV antigen was detected in the cytoplasm 
of scattered macrophages in marmoset and macaque lungs using IHC. Although it is 
possible that the viral antigen in some macrophages was due to phagocytosis, it has been 
shown that human macrophages can be productively infected with MERS-CoV,30 which 
may have resulted in the formation of multinucleated giant cells in the macaques and 
marmosets. 
Bronchointerstitial pneumonia developed in both rhesus macaques and common 
marmosets post-MERS-CoV inoculation; however, the percentage of the lung affected by 
lesions and infiltrated by neutrophils was significantly higher in marmosets. The higher 
pulmonary viral loads in marmosets may have induced a more robust inflammatory 
response resulting in increased neutrophil recruitment. Once in the lungs, neutrophils can 
degranulate or release reactive oxygen species, damaging pulmonary tissue and 
potentially exacerbating lesions and clinical disease severity.10,13  
At 3 dpi, no differences were detected for T lymphocyte, B lymphocyte or 
macrophage infiltration into the lungs of marmosets as compared to macaques. However, 
upregulation of genes or RNA transcripts associated with proinflammatory mediators has 
been shown in pneumonic lung at 3 dpi in both species.7,8 These results fit would be 
expected in the early phase of inflammation when an innate immune response is induced 
and neutrophils are the predominant effector cell type, prior to activation of the adaptive 
immune response.3,11 Marked changes in the numbers of infiltrating lymphocytes and 




Significantly higher pulmonary viral antigen and viral RNA loads were detected 
in marmosets as compared to macaques. The reason for the variation in virus replication 
rates in the lungs of these two species is unknown. The difference in pulmonary viral 
loads was most likely not caused by differences in DPP4 expression, since the location 
and extent of DPP4 expression in the lungs was similar in the macaques and marmosets. 
The pulmonary viral load disparity may be due to differences between old world and new 
world primates in their susceptibility to MERS-CoV infection and virus replication or 
differences in the innate immune response to a viral infection, which could lead to 
variations in MERS-CoV-induced disease severity. Differences in viral loads and virus 
replication or disease severity between old world and new world primates has been 
described for other viral infections.23,25,26 Additionally, anatomical differences between 
the respiratory tracts of marmosets and macaques may also influence disease severity. 
Alternatively, the more robust inflammatory response in the marmosets may have 
promoted MERS-CoV replication, causing higher pulmonary viral loads. It has 
previously been described that proinflammatory mediators and pathways can enhance 
replication of influenza A virus and herpes simplex virus type 1;15,19,20 similarly, MERS-
CoV replication may be enhanced in a proinflammatory environment, resulting in the 
higher viral loads observed in common marmosets. The increased pulmonary neutrophil 
infiltration, rather than the pulmonary viral load alone, in the marmosets likely caused the 
increased extent of the lesions, which led to more severe clinical signs. These results 
suggest that increased virus replication along with an intense immune response to MERS-




 The differences in MERS-CoV disease severity between rhesus macaques and 
common marmosets allow these two animal models to span the wide range of disease 
severity reported in MERS-CoV-infected humans. While both models can be used to 
investigate the pathogenesis of this disease, each model may be used for different 
applications. Rhesus macaques can serve as a model for mild MERS-CoV disease, which 
is increasingly reported in humans infected with MERS-CoV.17,18  Common marmosets 
are the more suitable model for severe, potentially fatal, cases of MERS-CoV disease, 
which are typically reported in individuals who have an underlying comorbidity or in 
older individuals. The severe bronchointerstitial pneumonia that develops in common 
marmosets inoculated with MERS-CoV makes marmosets an ideal model for testing the 
efficacy of medical countermeasures such as antivirals, therapeutics and vaccines. The 
smaller size of common marmosets favors this model for drug studies as it significantly 
lowers drug quantities; however, it precludes repeated blood sampling within a short 
timeframe and fewer species-specific reagents are available for marmosets as compared 
to rhesus macaques. These limitations suggest that rhesus macaques may be a more 
suitable model for vaccine studies if repeated analysis of immune parameters is warranted. 
Although each model may be better suited for various applications, together, these two 
nonhuman primate models will aid in investigations aimed at combating the ongoing 
occurrence of human cases of MERS-CoV disease. 
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Figure 5.1 MERS-CoV inoculated nonhuman primates develop bronchointerstitial 
pneumonia that is histologically similar in character but is more extensive in common 
marmosets. Representative sections of lung from a rhesus macaque (A and C) and 
common marmoset (B and D) euthanized 3 dpi. A. Unaffected pulmonary tissue 
(asterisk) adjacent to a focus of bronchointerstitial pneumonia. B. The lung is diffusely 
affected by bronchointerstitial pneumonia. C and D. The microscopic features of the 
bronchointerstitial pneumonia are similar in rhesus macaques and common marmosets. 
Alveolar septa and lumina are predominantly infiltrated by neutrophils and macrophages 
mixed with fibrin, hemorrhage and edema. E and F. The average histologic score for the 
bronchointerstitial pneumonia in marmosets is significantly higher, indicating the 
pneumonia is more severe and extensive in common marmosets at both 3 dpi (E) and 6 








Figure 5.2 A mixed population of multinucleated cells are widely scattered throughout 
the bronchointerstitial pneumonia in rhesus macaques (A and C) and common marmosets 
(B and D). A and B. IHC for Iba1 in sections of lung. The majority of the multinucleated 
cells express Iba1 (black arrows), indicating the cells are of macrophage origin. Insets 
show multinucleated cells that are not macrophages (red arrows), as indicated by their 
lack of Iba1 expression. C and D. IHC for pan cytokeratin in sections of lung. The 
majority of the multinucleated cells are not of epithelial origin and do not express pan 
cytokeratin (black arrows). Insets show multinucleated cells expressing pan cytokeratin 
(red arrows), indicating the cells are of epithelial origin. Original magnification, 40x 






Figure 5.3 MERS-CoV inoculated common marmosets develop more severe airway 
lesions than rhesus macaques. A. Respiratory epithelium in a bronchus exhibits focal loss 
of cilia (arrow) in a macaque 3 dpi. Rare inflammatory cells are present in the bronchial 
lumen. B. Respiratory epithelial cells in a bronchus are eroded and attenuated (arrows) in 
a marmoset 3 dpi. Neutrophils and foamy macrophages infiltrate the bronchial wall and 
mix with edema and hemorrhage in the bronchial lumen. C. Neutrophils and foamy 
macrophages with minimal edema, hemorrhage and fibrin are present in the wall and 
lumen of a bronchiole in a macaque 3 dpi. D. A bronchiole is occluded by a mat of fibrin 
(asterisk) mixed with edema, hemorrhage and degenerate leukocytes in a marmoset 4 dpi. 






Figure 5.4 Common marmoset lungs contain more MERS-CoV antigen than rhesus 
macaque lungs. A and B. IHC for MERS-CoV antigen in sections of lung from 
nonhuman primates necropsied 3 dpi. Lower amounts of viral antigen are present in 
macaques (A) than marmosets (B). Insets show the results of the ImageScope positive 
pixel count algorithm for the IHC-labeled lung sections. Red and orange pixels indicate 
detection of MERS-CoV antigen; blue pixels indicate tissue does not contain MERS-CoV 
antigen. C. The percentage of the lung containing MERS-CoV antigen is higher in 
common marmosets, as determined by digital analysis using ImageScope. D. Pulmonary 
viral RNA loads are significantly higher in marmosets at both 3 and 6 dpi. Original 







Figure 5.5 Quantification of inflammatory cells in the lung 3 dpi indicates pulmonary 
neutrophil infiltration is higher in common marmosets. A and B. IHC for 
myeloperoxidase, a marker for neutrophils, in lung sections. C. The percentage of the 
lung infiltrated by neutrophils is significantly higher in marmosets. No differences are 
noted for pulmonary infiltration by T lymphocytes (D-F), B lymphocytes (G-I) or 
macrophages (J-L) between macaques and marmosets. Insets show the results of the 
ImageScope positive pixel count algorithm on the IHC-labeled lung sections. Red and 
orange pixels indicate detection of specific inflammatory cell markers; cells not 
expressing the marker of interest are shown as blue pixels. Original magnification, 20x 






Figure 5.6 The location of inflammatory cells in the lung is similar in rhesus macaques 
and common marmosets. T lymphocytes are present on the periphery of lymphoid 
follicles (A), cuff blood vessels and are found in alveolar septa (B). B lymphocytes form 
lymphoid follicles near airways (C) and are found in alveolar septa (D). Macrophages are 
common in alveolar septa and lumina (E and F). IHC for CD3 (A and B), CD20 (C and 







Figure 5.7 DPP4 is expressed by the same cell types in rhesus macaques and common 
marmosets in the lung. IHC for DPP4 on sections of lung show DPP4 is expressed by 
airway epithelium and smooth muscle cells in macaques (A) and marmosets (B). Insets 












CHAPTER 6. SUMMARY AND FUTURE DIRECTIONS 
6.1 Summary of Research Findings and Future Directions 
 A large percentage of infectious disease outbreaks have been caused by emerging 
viral pathogens; the number of these outbreaks reported has been rising nearly every 
decade since the 1940’s.4,5 Since many of these emerging viruses are transmitted from 
wildlife reservoirs to humans, it is no surprise that changes that have led to increased 
interactions between humans and animals, such as deforestation and urban sprawl, have 
been reported in association with disease outbreaks.2,3 As of yet, there are no accurate 
methods to pinpoint the geographic location where the next virus will emerge. 
Furthermore, it is currently not feasible to predict the next wildlife species that will 
transmit a novel virus to humans, nor is it possible to prevent human contact with 
potential wildlife reservoirs. It has been estimated that there are at least 320,000 viruses 
in mammals alone which have yet to be discovered and we have no clue as to which of 
these viruses will have zoonotic potential.1 As such, viral infections will continue to 
emerge and cause disease in humans. Since many of these emerging viruses cause 
significant disease or death in humans it is vital to study the pathology and  
pathogenesis of these novel viruses as they are discovered in order to detect patterns in 
their mechanisms of disease. This information could then be used to develop broad 





quench outbreaks as they arise. Therefore, the purpose of the research presented here was 
to use animal models to characterize the respiratory tract pathology and pathogenesis of 
two emergent viral respiratory infections. Additionally, since MERS-CoV was just 
isolated for the first time in 2012, the aim was also to evaluate recently developed animal 
models of MERS-CoV infection.  
 In regard to Nipah virus, our initial research on the late stages of Nipah virus 
disease in hamsters prompted us to study the early pathogenesis of Nipah virus in order to 
identify the initial target organs and target cells. In our early pathogenesis study, Nipah 
virus first targeted the lung and nasal cavity and virus replication was detected in the 
respiratory tract by 8 hpi. However, by 48 hpi we still did not detect infectious virus or 
virus replication in the brain or infection of blood vessels in organs other than the lung. 
These results suggested that antivirals aimed at inhibiting virus replication would be of 
most benefit if rapidly administered into the respiratory tract and that early treatment may 
prevent virus replication in the brain and widespread infection of the vasculature, thus 
lessening disease severity. This could be tested by administering an antiviral to groups of 
hamsters at a scheduled time point post Nipah virus inoculation, such as either 4, 8, 16, 
24, 32 or 48 hours post inoculation and then scoring clinical signs on a daily basis and 
analyzing tissues and blood for virus dissemination, virus replication and lesion severity 
at scheduled endpoints. 
The studies reported here focused on the respiratory component of Nipah virus 
disease; however, neurologic disease and encephalitis also play an important role in 
human Nipah virus infections. Therefore, it would be valuable to study virus 





system. Our Nipah virus early pathogenesis study concluded at the 48 hour post 
inoculation time point, which was prior to the development of lesions in the central 
nervous system. Thus, an experiment similar to the early pathogenesis study, but which 
would document disease development in the central nervous system and blood vessels in 
multiple organs over time in Syrian hamsters, would be especially useful. Sampling of 
hamsters at consecutive time points, such as every 8 hours, from 2 days post inoculation 
to development of end-stage clinical disease would provide additional insight into how 
Nipah virus disseminates from the respiratory tract to blood vessels in essentially every 
organ and to the central nervous system.  
Since MERS-CoV was only first identified in 2012, there is still much to learn 
about this virus in terms of the lesions it causes, its transmission routes, pathogenesis and 
identification of host enzymes or co-factors that aid virus uptake into host cells or virus 
replication. In this dissertation we focused on the comparative respiratory tract pathology 
of available animal models of MERS-CoV infection. In nonhuman primate models we 
noticed differences in the disease severity that developed post MERS-CoV inoculation, 
which appeared to be associated with increased virus replication and a more robust 
immune response to virus replication. Future studies should focus on pinpointing the 
cause of the increased virus replication rate in common marmosets because of its 
association with severe, potentially lethal disease. Rhesus macaques and common 
marmosets have an identical amino acid structure in the region of DPP4 that binds the 
MERS-CoV spike protein and exhibit similar patterns of DPP4 expression in the lung. 
This suggests that differences in virus replication rates are unlikely to be caused by 





research could focus on mechanisms of virus entry into host cells, identification of 
cellular machinery that is used for virus replication or which could inhibit or slow virus 
replication, and the acute immune response to MERS-CoV. Differences in any of these 
components between rhesus macaques and common marmosets could be responsible for 
the variation in the MERS-CoV replication rates. Once this knowledge is available, it 
could be used to limit virus replication, potentially lessening disease severity and the case 
fatality rate. 
Although several animal models of MERS-CoV have been developed, we still do 
not know which of these models best recapitulates MERS-CoV disease in humans. 
Therefore, procuring and studying autopsy data from fatal human cases would provide 
vital information on the pathogenesis of MERS-CoV disease in naturally acquired 
infections. Furthermore, although the pathology of MERS-CoV has been documented in 
experimentally inoculated dromedary camels, it would be interesting to determine if the 
same lesions are observed in naturally infected dromedary camels in the Middle East. 
This could be analyzed by performing necropsies on dromedary camels that are actively 
shedding infectious virus. Additionally, transmission studies using one or more of the 
available animal models of MERS-CoV infection could help determine how MERS-CoV 
is transmitted from wildlife reservoirs to humans and among humans.  
 
6.2 Conclusion 
The research presented here shows how the development and characterization of 
animal models of viral infections helps elucidate the pathology and pathogenesis of 





routes of viral shedding and transmission, decipher the best sample types for diagnosing 
infections, identify the most effective route for administering antivirals or vaccines and 
be used to test antiviral or vaccine efficacy. Together, this information aids in the overall 
goal of managing and mitigating current and future emerging viral infections.  
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